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A
ABO-incompatible transplant, hemolytic anemia (abst) . . . 362
Acetazolamide, NaHCO1 cotransport, PT (abst) 680
Acid-base balance. See pH
Acidosis
adaptation trade-offs, Nephrology Forum 1205
chronic renal, urinaly parameters, pH 624
metabolic, anion gap, HD (abst) 354
metabolic, CRF (abst) 355
metabolic, hyperkalemia therapy (abst) 355
osteoblastic intracellular pH and Ca 1790
renal osteodystrophy, Nephrology Forum 1816
Actin, aminopeptidase A, BBM (abst) 1220
Acute bacterial nephritis
characteristics (abst) 344
clinical aspects (abst) 344
Acute pyelonephritis graft kidney, RF (abst) 362
Acute renal failure (ARF)
continuous hemofiltration (abst) 989
erythropoietin in (abst) 974
fibrinolysis, prostaglandins, ET-1 (abst) 996
insulin-like growth factor-i 1658
ischemic, differing HD membranes (abst) 985
post-extracorporeal circulation (abst) 343
post-transplant (abst) 968
pre-eclampsia (abst) 1004
recovery with zaprinast 1569
Acute respiratory alkalosis, plasma protein response 217
Acute tubular necrosis, cytoresistance, hypoxic injury 628
Adenosine
extracellular ATP, mitogenic effect, MC (abst) 1000
extracellular NaC1, TAL (abst) 681
hypersensitivity, glomeruli, low-Na rats (abst) 686
infusion rate, renal effect (abst) 699
Na transport, A1 receptor, [Ca2]1 1576
signaling, human CD cells 1310
transjunctional, cs2-autoreceptors (abst) 996
Adenovirus-mediated gene transfer 322
Adenylate cyclase, desensitization, PKC, PTH 38
ADH, Na/H exchange, Ang II, diadenosines, CCD (abst).. 999
Adhesion molecules
biopsy, post-transplant (abst) 370
hemorrhagic fever with renal syndrome (abst) 350
proteins interact with HD membranes 1115
Adipocytes, elevated cytosolic Ca, CRF 1624
Adriamycin
glomerulopathy, fibronectin, silibinin (abst) 673
nephrosis, ACEi, Ang II, bradykinin (abst) 1223
Advanced glycosylation end products (AGEs)
ECM gene expression, DM, GS 49:S-55
formation, PD fluid 1768
Afferent arteriolar response, Tolrestat (abst) 1221
Age
antihypertensive agents, compared (abst) 962
infradian bioperiodicity, urinary enzymes (abst) 968
intrarenal resistance index, EH (abst) 986
pediatric donor kidney matching (abst) 996
rejection episodes (abst) 997
Albumin
apoprotein B degradation 421
based PD solutions (abst) 358
binding, glomerular capillary wall 1031
Albuminuria. See also Microalbuminuria
ANP, natriuresis, glomerular permeability, NS (abst) ... 993
CsA-associated arteriopathy, proteinuria (abst) 1008
heparan sulfate, GBM, lupus nephritis (abst) 701
Na intake, EH (abst) 992
single nephron 1078
single nephron (abst) 1217
Alkalosis, acute respiratory, K response 217
Alloantibodies, "early graft dysfunction" (abst) 972
Allogeneic transplantation, tolerance (abst) 706
Allografts
acute pyelonephritis, RF, post-transplant (abst) 362
biopsy, interstitial edema, infiltrate (abst) 703
biopsy during rejection (abst) 703
GFR pre/post-transplant (abst) 360
hyperparathyroidism (abst) 965
metabolic risk factors (abst) 979
nonimmunologic late graft loss, Nephrology Forum ... 1470
optimizing survival (abst) 981
recipient IgA nephropathy (abst) 361
sex/age and survival (abst) 707
survival, hypertension and race 1136
tolerance induction, coichicine (abst) 368
a-ketoglutarate, PAH secretion (abst) 663
a2-autoreceptors, adenosine (abst) 996
Alport syndrome
asymptomatic women carriers, living donors (abst) 371
autosomal recessive 1142
basement membrane molecular genetics 49:S-29
bull terrier hereditary nephritis 758
COL4A3 gene mutation 1199
prenatal diagnosis 327
Aluminum hydroxide, serum Al, ESRD (abst) 354
Aluminum toxicity
microcytosis 164
RI and transplantation (abst) 983
AMBIO dialyzer biocompatibility (abst) 966
Amino acids
based dialysate, malnourished CAPD patients 1148
free, cortex and outer medulla, ischemia (abst) 991
oxidative phosphorylation diseases 1101
PT gp330, endocytosis, aprotinin (abst) 679
rBAT and heavy metal intoxication 1677
21-aminosteroids, renal injury 592
Aminoaciduria, oxidative phosphorylation diseases 1101
Aminoguanidine, IGF-1, NOS (abst) 685
Aminopeptidase A
actin, brush border membranes (abst) 1220
monoclonal anti-APA antibodies, PT (abst) 1221
Aminopeptidase N, EGF, 5'-NU, glomerular MC (abst)... 699
Amyloidosis, plasma exchange, cytotoxic drugs (abst)... . 1485
Analgesic nephropathy, urothelial carcinoma, post-
transplant (abst) 984
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autoimmune hemolytic, ABO-incompatible transplant
(abst)
renin-angiotensin axis, CRF (abst)
Angiogenesis
cytokines, proteolysis (abst)
pp60c-src, activated PDGF (abst)
stimulated by rHuEPO
Angiotensin (1-7), renal response (abst)
Angiotensin-converting enzyme (ACE) gene and DN....
Angiotensin-converting enzyme (ACE) inhibition
Ang II blockade, 2-K, 1-C hypertension
antiproteinuria, adriamycin nephrosis (abst)
antiproteinuria, renal/systemic hemodynamics (abst).
endothelin, prevent RF/death
glomerular filtration, mesangial volume (abst)
intrarenal, Ang I and II
plasma lipids, DN
Angiotensin I (Ang I), intrarenal ACEi, renal response
Angiotensin II (Ang II)
ET, mitogenic response, endothelial cells (abst)
heparan sulfate proteoglycans, MC (abst)
modulates PDGF
Na/H exchange, ADH, diadenosines, CCD (abst)
PKC, proximal tubule (abst)
renal nerve, RPP reduction (abst)
Angiotensin II (Ang II) receptors
antagonist, obstructive nephropathy 1285
blockade, antidiuresis, anti-natriuresis (abst) 668
ontogeny, 140, 1095
Angiotensinogen, antisense, transgenic mice 1638
Anionic horseradish peroxidase, charge selectivity 1630
Anionic transport, peritoneal mesothelium, SITS and
DIDS (abst)
Antegrade pyelography, acutely dilated pyelon (abst)
Anti-glomerular basement membrane (GBM) antibodies
GN, glomerular crescent formation (abst)
Goodpasture's disease (abst)
Anti-HLA-I antibodies, anti-idiotypic antibodies,
platelets (abst) 1483
Anti-infective therapy and RI (abst) 982
Anti-myeloperoxidase (MPO) antibodies
ANCA-associated GN 193
ischemia/reperfusion injury, GN 1121
microscopic polyarteritis, transplantation (abst) 368
nephrotoxic serum nephritis 454
Anti-natriuresis, stress induced, Ang lIr blockade (abst). . . 668
Anti-neutrophil cytoplasmic autoantibodies (ANCA)
anti-MPO antibodies and GN 454
GN, anti-PR3 renal disease 193
proteinase 3, Wegener's granulomatosis 1528
vasculitis, ANCA isotype, pulmonary hemorrhage
(abst) 365





allogeneic transplant, tolerance (abst) 706
Wegener's granulomatosis (abst) 708
Antibiotic prophylaxis, staphylococcus, CRIs (abst) 994
Antibodies, glomerular deposits, isoelectric point (abst). . 1006
Anticardiolipin antibodies, vascular access clotting, SLE
(abst) 1484
Antidiuresis, stress induced, Ang lIr blockade (abst) 668
Antiendothelial antibodies, Wegener's granulomatosis
362 (abst) 973
354 Antihypertensive agents
antiproteinuric effects (abst) 1223
659 elderly, compared, children (abst) 962
660 elderly, microalbuminuria (abst) 962
740 long-term therapy, DN, GFR 1726
975 microalbuminuria (abst) 962
1176 renal effects, early CRF (abst) 353
Antiphospholipid antibodies (APA)
1394 HD patients (abst) 1481
1223 SLE (abst) 369
1224 Antiproteinuric effect
1319 ACEi, adriamycin nephrosis (abst) 1223
676 ACEi, renal/systemic hemodynamics (abst) 1224
274 antihypertensive agents (abst) 1223
907 Antisense angiotensinogen, transgenic mice 1638
274 Antisense oligonucleotides, genes, organ development
(abst) 693
687 Aortic valve regurgitation, hypertensive nephrosclerosis
701 (abst) 981
131 Apolipoproteins
glomerular deposits, analbuminemia (abst) 706
696 renal deposits, UNX analbuminemia 442
1220 Apoprotein B degradation, albumin 421
Apoprotein(a) isoforms, atherosclerosis, CAPD (abst) . . . . 965
Apoptosis
clusterin expression, renal regeneration 411
glomerulonephritis (abst) 657
HgCl2 T-cell hybridoma, cytokines (abst) 694
intrarenal, hypoxia 1806
neutrophils, CD36 eDNA transfection (abst) 671
683 proliferative GN 114
964 proliferative GN (abst) 688
AQP-CD water channel, vasopressin (abst) 696
350 Arteriopathy
350 CsA-associated, proteinuria, albuminuria (abst) 1008
CsA-associated, renal biopsy (abst) 998
Arteriovenous fistulae
clotting, coagulation abnormalities (abst) 1484
PTFE grafts, seroma formation (abst) 1484
Aspirin, renal ammoniagenesis (abst) 664
AT-ir antagonist, essential hypertension (abst) 1216
Atherosclerosis, CAPD patients (abst) 965
ATP
extracellular, membrane voltage, MC (abst) 700
extracellular, mitogenic effect, MC (abst) 1000
extracellular, Na transport, PKC (abst) 705
mitochondrial synthase, developing kidney (abst) 679
phospholipase C, c-fos, P2u-receptors, MC (abst) 669
Atrial natriuretic factor (ANF), compared, urodilatin. . . . 1558
Atrial natriuretic peptide (ANP)
growth suppression, MC, TGF-/3 (abst) 692
ICV immunoneutralization, renal function (abst) 682
natriuresis, albuminuria, glomerular permeability, NS
(abst) 993
plasma concentration, HD (abst) 1002
renal hemodynamics, acute volemic stress (abst) 686
sino-carotid denervation, endocrine function (abst) 683
sino-carotid denervation, renal function (abst) 668
Autoimmune hemolytic anemia, ABO-incompatible
transplant (abst) 362
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Autosomal dominant polycystic kidney disease (ADPKD)
autoregulatory reserve (abst) 995
clinical study (abst) 354
epithelial differentiation 716
ET-1 role (abst) 995
fibroblast growth, ECM metabolism 727
genetic study 728, 729
genotype and phenotype (abst) 985
molecular basis 715
new mouse PKD mutant 552
normotensive, i.v. dopa (abst) 1218
pressure-dependent renin secretion (abst) 967
prognosis, primary hypertension (abst) 1002
solute and fluid secretion 723
transplantation (abst) 368
tubulogenesis, cyst-derived cells 861
Autosomal recessive polycystic kidney disease (ARPKD)
EGFr expression, CPK mouse kidney 490
MMP expression and TIMP (abst) 659
molecular basis 715
new mouse PKD mutant 552
Azathioprine
compared, CsA monotherapy (abst) 975
glomerular barrier function, CsA (abst) 1221
B
Babylonia, ancient, renal/urinary tract disease 1811
Bacteremia, E. col4 interstitial nephritis (abst) 986
Bacterial infection
HCV, HBsAg, CD14, HD (abst) 999
LPS-induced GN, INF-y (abst) 974
LPS-induced IL-6 gene, cAMP (abst) 694
spectrum UTI, post-transplant (abst) 1005
superantigen, MRSA infection, nephritis 207
Baculovirus-infected cells, renal Na/P1-cotransport (abst) . . 662
Barium effect, Na reabsorption (abst) 663
Bartter syndrome with hypocalciuria (abst) 364
Basement membranes
AGEs induce ECM gene overexpression, DM, GS.. 49:S-55
cell-cell cross-talk, interstitial renal fibrosis 49:S-48
cell-extracellular interactions, signalling 49:S-8
crinopexy 49:S-15
ECM remodeling 49:S-12
models of nephron reduction 49:S-51
molecular genetics, Alport syndrome 49:S-29
renal disease progression, chemokines 49:S-44
structure, supramolecular organization 49:S-4
TGF-f3, an overview 49:S-19
TGF-13 mediates US 49:S-59
J3 integrin
crescentic UN (abst) 370
expression, ICAM-1, MC, GN (abst) 352
expression, ICAM-1, MC, high glucose (abst) 352
J32-adrenoceptor-agonists
hyperkalemia therapy (abst) 969
hypokalemia, lactatemia post-therapy (abst) 969
J32-microglobulin
adsorption, HD membranes (abst) 356
bone disease and 1
bone loss, IL-113, prostaglandins 587
deposits, math model for 1453
urinary excretion, membranous nephropathy (abst).... 1218
f33 integrin, crescentic GN (abst) 370
Bicarbonate
excretion, regulation by kallikrein (abst) 681
loss, theophyllin, UTI, DM, post-transplant (abst) 1001
transport, medullary hypotonicity (abst) 667
Biocompatibility
dialysis membranes, oxygen radicals as marker (abst) . . . 995
dialyzer elution technique (abst) 1218
HD membranes compared (abst) 966
Bioelectrical impedance analysis (BIA) (abst) 987, 993
Biopsy. See Renal biopsy
Biphasic TNF-a in MRL-lpr mice 122
Blood pressure
24-hour monitoring with FK506, CsA (abst) 977
ambulatory monitoring, EH, salt intake (abst) 978
antihypertensives, antiproteinuric effects (abst) 1223
arterial/venous changes, uremia (abst) 963
enalapril, nifedipine, renal response, ET (abst) 1216
heparin lowers 1017
insulin sensitivity, CsA therapy (abst) 987
renin mRNA, renin secretion, RA stenosis (abst) 978
vessel wall properties, post-transplant (abst) 964
Body fluid composition, evaluation with BIA (abst) 993
Bone disease
acidosis and renal osteoclystrophy, Nephrology Forum . 1816
/32-M, IL-113, prostaglandins 587
(32-M as mediator 1
IGF-1 mRNA in GH-treated uremic bone 1374
low turnover osteopathy, long-term HD (abst) 1000
osseus malformations, nephronophthisis (abst) 1008
pre-dialysis/dialysis patients 1434
secondary hyperparathyroidism, uremia, DM 1746
Bone marrow
allogeneic transplant, tolerance (abst) 706
CsA increases plasma prorenin (abst) 966
fibrillary deposits, immunotactoid-like glomerulopathy
(abst) 998
transplant, CsA, arteriopathy (abst) 1008
Bone metabolism
children, NS, steroids (abst) 347
low-calcium dialysate, CAPD (abst) 969
mass reduction dynamics, HD patients (abst) 983
Bone mineral density, Ca transport, hypercalciuria (abst). . 363
Bradykinin, antiproteinuria, adriamycin nephrosis (abst). . 1223
Brain natriuretic peptide, plasma concentration, HD
(abst) 1002
Brush-border membranes
actin, aminopeptidase A (abst) 1220
Cl conductance, porcine (abst) 971
fluidity, Na-coupled uptake, cisplatin 1048
human urine, proteins mark PT injury (abst) 965
inositol lipid signalling system (abst) 686
renal tubular enzymes, urinary excretion (abst) 989
BT563 (anti-IL-2R MoAb) prevents rejection (abst) 708
Bull terrier hereditary nephritis 758
Bumetanide, pharmacokinetics, NS (abst) 354
C
c-fos expression
calcium channel blocker, ischemic injury (abst) 343
extracellular ATP, phospholipase C, P2u-receptors,
MC (abst) 669
C-type natriuretic peptide
plasma concentration, HD (abst) 1002
proinsulin, neuropeptide Y, Na/K-ATPase (abst) 678
receptors, human MC (abst) 682
Clq, IgG binding, mesangial cells (abst) 671
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Clq nephropathy
biopsy analysis (abst) 347
with minimal change NS (abst) 347
C3
biosynthesis, human mesangial cells 829
local transcription, allograft rejection (abst) 371
C4, MC synthesis, cytokines, MHC antigen (abst) 671
C4d, capillary deposits, "early graft dysfunction" (abst) . . . 972
C6 deficiency, active Heymann nephritis 1604
Ca2
activated K channel, human colonic T84 cells (abst). . . . 680
dependent Cl conductance (abst) 991
extracellular nucleotides, cortical TAL (abst) 700
influx, epithelial cells (abst) 972
oscillations/interactions, RAS oncogene (abst) 669
osteoblastic intracellular, acidosis 1790
oxidant-induced PT cell injury (abst) 343
[Ca2I
adenosine, Na transport, A1 receptor 1576
adipocytes, chronic renal failure 1630
carbohydrate metabolism, PMNL, verapamil 1741
PTH-PTHrP receptor of heart, CRF 1182
Calcitriol
i.v., insulin sensitivity, uremia 200
oral, zero calcium solutions, CAPD (abst) 369
oral bolus, predialysis CRF (abst) 991
Calcium
absorption, Bartter syndrome, hypocalciuria (abst) 364
cell regulation, renin gene expression, cAMP 1266
erythrocyte transport, hypercalciuria (abst) 363
intestinal absorption, bone mineral density (abst) 363
intracellular, ouabain-like factor, inner medullary CD
cells (abst) 1006
renal renin secretion (abst) 675
Calcium channel blockers
cellular Ca, cell injury, anoxia, PT (abst) 702
EGF, c-fos gene expression, ischemia (abst) 343
felodipine, H 186/86, hypoxic PT (abst) 702
Na/K-ATPase, acute ischemic RF (abst) 345
Calcium dialysate
Ca-free levels, HD, hypercalcemia (abst) 356
Ca-low levels, bone metabolism, CAPD (abst) 969
Calciuria, K-deprivation, salt restriction 899
Calculi, ESWL monotherapy (abst) 345
Cancer
factors associated with transplantation (abst) 980
lymphoma incidence post-transplant (abst) 988
malignant lymphoma, EBV, post-transplant (abst) 980
malignant tumors post-transplant (abst) 1006
renal cell carcinoma, peripheral T-cell subsets (abst) . . . 345
urothelial, analgesic nephropathy, post-transplant
(abst) 984
Captopril, L-arginine, nitric oxide, CRF 1515
Carbamylated hemoglobin as index of uremia (abst) 1219
Carbohydrate metabolism, [Ca2]1 PMNL, verapamil. . . . 1741
Cardiac interstitial fluid, RAS components (abst) 703
Cardiac myocyte function, CRF (abst) 684
Cardiac PTH-PTHrP receptor, [Ca2} CRF 1182
Cardiovascular disease
cardiac rhythms, ESRD, HD 1443
CHF, dialysis patients 884
complications, post-transplant (abst) 980
coronary artery calcification (abst) 967
events post-transplant (abst) 979
ischemic, Lp(a), CAPD (abst) 357
patients starting ESRD therapy 186
prevention, HD (abst) 987
Carotid artery, structural changes, CRF (abst) 998
Cathepsin S
catalytic activity, PT (abst) 1000
in kidney (abst) 665
Catheter-related infections, prophylaxis (abst) 994
Cationized Ig aggregates, glomeruli (abst) 688
CD14
HCV, HBsAg, bacterial infections, HD (abst) 999
soluble, high serum levels, HD (abst) 973
CD16, (Fcy receptor III), glomerular MC (abst) 670
CD36, cDNA cell transfection, neutrophils, apoptosis
(abst) 671
CD43, release from neutrophil membrane (abst) 672
CD44, neutrophil proteases, induce MC shedding (abst) .. 671
CD59, urinary, complement SC5b-9, cytokines, MGN.... 1403
cDDP, BBM fluidity, Na-coupled uptake 1048
Cell-cell cross-talk, interstitial renal fibrosis 49:S-48
Cell-extracellular matrix interactions 49:S-8
Cell volume
effects on pH, acidic cellular compartments (abst) 681
oscillates with migration of MDCK-F cells (abst) 697
regulation, cloned Cl channel from EC (abst) 674
Cerebrovascular complications, post-transplant (abst) 980
CFTR, cloning, mutations and functions 720
cGMP
activating agonists, membrane voltage, CCD (abst) 999
intracellular synthesis, somatostatin, MC (abst) 666
Channels and pumps (abst) 657
Charge selectivity 1242, 1630
Chemokines
glomerular, nephrotoxic nephritis (abst) 660
renal disease progression 49:S-44
Children
antihypertensive therapy (abst) 962
complement, serum/dialysate, CAPD (abst) 705
FSGS, distribution of lesions 1690
NS, bone metabolism, steroids (abst) 347
NS, mild, steroid-responsive 1392
NS, sonography (abst) 346
NS, urinary f32-M, proteinuria (abst) 346
pyeloplasty, UUO (abst) 344
reflux nephropathy, glomerular morphometry 1108
treatment of CRF, Nephrology Forum 951
CHIP-FA amphibian water channel (abst) 662
Cholesterol loading, lipoprotein(a), MC (abst) 989
Chronic renal failure (CRF)
adipocytes, [Ca2}, 1624
anemia, renin-angiotensin axis (abst) 354
captopril, L-arginine, nitric oxide 1515
cardiac myocyte function (abst) 684
carotid artery, structural changes (abst) 998
children, Nephrology Forum 951
chronic viral hepatitis 1231
cytokine autoantibodies (abst) 998
excess PTH, lung and right ventricle 158
exercise, serum K changes (abst) 969
heart PTH-PTHrP receptor, [Ca2J1 role 1182
hepatocyte metabolism 1522
Lp(a) and lipid profiles (abst) 357
metabolic acidosis (abst) 355
oral calcitriol bolus, predialysis (abst) 991
protein intake, anti-hypertensives (abst) 353
protein intake, urine concentration 7
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serum/urine neopterins (abst) . 353
torasemide therapy (abst) 992
Cirrhosis, renal ET-1 receptor subtypes (abst) 976
Cisplatin
epithelial transport system (abst) 343
modulated Na-coupled uptake, BBM fluidity 1048
Cl-
channels, EC, cell volume regulation (abst) 674
conductance, BBM vesicles (abst) 971
conductance, Ca-dependent, MC swelling (abst) 991
dependent taurine reabsorption, furosemide (abst) 997
intake, hypertension, PKD (abst) 973
renin secretion, juxtaglomerular cells (abst) 675
transport inhibitors in epithelia 722
"Clearance peak" PD prescription model (abst) 371
Clearance study
Na reabsorption, Henle's loop (abst) 667
tubular site of action, furosemide (abst) 682
Clusterin expression, apoptosis, renal regeneration 411
Coagulation
endothelin role 795
regulatory protein loss, thrombosis, CAPD (abst) 990
COL4A3 gene mutation, Alport syndrome 1199
COL4A5, prenatal diagnosis of Alport syndrome 327
Coichicine, allograft tolerance (abst) 368
Collagen
GS, progression predictors 49:S-39
molecular properties, diseases of 49:S-24
Collagen-I
subchains, differential expression, GS (abst) 698
synthesis regulation 49:S-34
Collagen-IV
distribution, Alport syndrome 1142
EHS, lacking Goodpasture's epitope, GN 404
regulation, s5(IV), NIH3T3 cells (abst) 698
Collagenase-IV
92/72-kDa, SV4O oncogene, collecting tubule (abst) .... 665
5' region, 72 kD, MC enhancer (abst) 974
Collecting ducts
92/72-kDa collagenase-IV, SV4O oncogene (abst) 665
adenosine signaling 1310
enriched rabbit cortical, ficoll gradient 306
inner medullary, acid-base transport, Nephrology
Forum 333
inner medullary, organic osmolytes, G-proteins (abst). . . 996
intercalated cell properties, MDCK cells 679
papillary, Na transport, interstitial cell culture (abst) . . . 973
papillary pH gradient, urine, vasa recta, diuresis
(abst) 681, 987
principal cells, proteoglycans, Simian virus 40 (abst). . . . 698
WCH-CD endosome distribution, vasopressin (abst). . . . 675
Complement
active Heymann nephritis 1604
anti-thymocyte-antibody, renal hemodynamics (abst). ... 686
Clq subunit, IgG binding, MC (abst) 671
deposits, "early graft dysfunction" (abst) 971
Factor B and C4, MC, cytokines, MHC antigen (abst) . . 671
local transcription, rejection (abst) 371
SC5b-9, urinary, CD59, cytokines, MGN 1403
serum/dialysate, children, CAPD (abst) 705
terminal cascade activation, renal infarction 918
Computer tomography, coronary arteries (abst) 967
Conductivity kinetic model (abst) 367
Congestive heart failure and dialysis 884
Connective tissue disease, membranous GN (abst) 987
Continuous ambulatory peritoneal dialysis (CAPD). See
also Dialysate
acid-base balance in 269
atherosclerosis 965
BIA, body fluid composition (abst) 993
bone disease, PTH response 1434
Ca dialysate, low-level, bone metabolism (abst) 969
Ca dialysate, zero-level, oral calcitriol (abst) 369
complement in serum/dialysate, children (abst) 705
intraperitoneal cytokines, without peritonitis (abst) 994
lactate-buffering, mesothelial cell function 282
long-term experience, 164 patients (abst) 966
Lp(a), ischemic heart disease (abst) 357
nitrate levels (abst) 1217
nutritional assessment, HD (abst) 359
nutritional assessment, urea kinetic modeling (abst) . . . . 358
peritoneal fibrinolysis, mesothelial cells (abst) 997
peritoneal fibrosis, peritonitis (abst) 358
pregnancy with (abst) 1004
quantification, clinical outcome (abst) 978
rhGH effects, undernourished adults (abst) 359
standard peritoneal permeability analysis, PET (abst) . . 1217
thrombosis, coagulation regulatory protein loss (abst)... 990
Contrast media
iodine monitoring, RI (abst) 983
ionic/nonionic, nephrotoxicity 254
nephrotoxicity, N-acetyl-f3D-glucosaminidase (abst) 342
nitrendipine, urinary enzyme, protein excretion (abst). . . 369
nonionic, pharmacokinetics, RI (abst) 988
Coronary artery disease
calcifications, non-invasive measurement (abst) 967
risk assessment, elderly, pre-transpiant (abst) 368
Cortical collecting ducts
cell volume dependent NA,K!ATPase pump (abst) 659
cGMP activating agonists, membrane voltage (abst). ... 999
enriched rabbit, ficoll gradient 306
microtubule content increase, cAMP (abst) 662
Na/H exchange, ADH, Ang II, diadenosines (abst) . . 999
Na transport, extracellular ATP, PKC (abst) 705
Crescentic glomerulonephritis
i3 integrin, ICAM-1, VCAM-1 counter-receptors
(abst) 370
IL-Ira halts established 1303
Crinopexy, extracellular regulation of GF action 49:S-15
Crush syndrome, ET receptor antagonism (abst) 1483
Cryoglobulinemia, HCV, renal involvement (abst) 367
CTLA4Ig
as novel antirejection strategy 241
short-term immunosuppression (abst) 370
Cuprophane membranes, AMBIO dialyzers compared
(abst) 966
Cyclic adenosine monophosphate (cAMP)
adenosine signaling, CD cells 1310
cell regulation, renin gene expression 1266
dexamethasone, IL-1J3-induced NOS, MC (abst) 992
GFR elevation, glucagon, urea (abst) 685
IL-i induces IL-8, IL-6 in human MC (abst) 687
LPS-induced IL-6 gene expression (abst) 694
microtubule content increase, CCD (abst) 662
protein kinase, glomeruli function (abst) 688
as second messenger, organic anion transport (abst). . . . 977
Cyclooxygenase-Il
ET-1, mesangial cells 53
gene expression, tyrosine phosphorylation, IL-1f3 1354
Cyclooxygenases, IL-i regulation, MC (abst) 686
1882 Subject Index: Vol. 47
Cyclosporin A
ET-1, cell-cell interaction (abst) 670
NO generation, endothelial cells (abst) 670
NS, children, INF-y, steroids, lgE-R2 (abst) 346
plasma prorenin in bone marrow (abst) 966
urinary TxB2 PGF1 post-transplant (abst) 360
Cyclosporine
arteriopathy, proteinuria, albuminuria (abst) 1008
autoimmune hemolytic anemia, ABO-incompatible
transplant (abst) 362
blood trough level variability (abst) 370
glycosylation (abst) 1481
membranous nephropathy 1130
urinary ET, post-liver transplant 1426
Cyclosporine A
24-hour BP monitoring, FK506 (abst) 977
arteriopathy on renal biopsy (abst) 998
dietary fatty acids, GFR 611
glomerular barrier function, azathioprine (abst) 1221
inhibits cell proliferation, TGF-f3 (abst) 1006
insulin sensitivity, BP (abst) 987
monotherapy compared, azathioprine (abst) 975
nephrotoxicity, arginine, modulated by NO 1507
nephrotoxicity, lipid peroxidation, vitamin E 927
psoriasis, RAS, renal hemodynamics (abst) 704
renal function, serum electrolytes (abst) 977
Sandimmun-Neoral conversion (abst) 990
vascular reactivity (abst) 360
Cystathionine serum concentration, uremia (abst) 964
Cystatin C, as marker of GFR 312
Cytokines
angiogenesis, extracellular proteolysis (abst) 659
autoantibodies characterized, CRF (abst) 998
autocrine regulation human MC, GF (abst) 692
fibronectin production, MC (abst) 673
HgCl2-induced apoptosis, T-cell hybridoma (abst) 694
intraperitoneal, CAPD without peritonitis (abst) 994
MC expression ICAM-1, MNC, IgA nephropathy
(abst) 352
MC synthesis complement, MHC antigen (abst) 671
modulate human MC biosynthesis of C3 829
regulate U-937 monocyte MC adhesion (abst) 660
urinary, complement SC5b-9, CD59, MGN 1403
Cytotoxic drugs, plasma exchange, amyloidosis (abst). . . . 1485
0
DDAVP vasodilator effects, EH (abst) 706
Decorin mRNA, TGF-13, DN (abst) 678
Defiazacort, NS, children, bone metabolism (abst) 347
Degranulation inhibiting protein (DIP), uremia (abst) . . . . 672
Dehydration, WCH-CD endosome distribution, CD
(abst) 675
Dermal angiopathy, HD patients 1775
Desferrioxamine, plasma endothelin, HD (abst) 356
Dexamethasone, NOS, IL-lp, cAMP, MC (abst) 992
Dextran sulfate uptake by glomerular cells 945
Dextrans induce IgAGN in rats (abst) 691
Diabetes Control and Complications Trial 1703
Diabetes insipidus (DI)
intracranial calcifications (abst) 364
X-linked nephrogenic, gene mutation (abst). .. 344, 364, 991
Diabetes mellitus (DM)
effect on PET with peritonitis 1760
glomerular changes, microalbuminuria (abst) 674
lipid profile, with/without nephropathy (abst) 985
pancreas/kidney transplant, UTI, NaHCO3 loss,
theophyllin (abst) 1001
patient/graft survival (abst) 981
post-transplant predisposition (abst) 975
renal hypertrophy and proto-oncogenes 782
risk factors for RRT (abst) 366
secondary hyperparathyroidism, bone disease, uremia.. 1746
Diabetic nephropathy (DN)
ACE gene polymorphism 1176
AGEs induce ECM gene overexpression, GS 49:S-55
antihypertensives, long-term therapy, GFR 1726
de novo GS, post-transplant (abst) 970
dipyridamole effects (abst) 678
ESRD, epidemiology (abst) 988
experimental, cellular events in 935
fibronectin, cytoprotection, cultured MC (abst) 673
GBM heparan sulfate changes (abst) 701
glomerular HS-PG mRNA expression (abst) 351
glomerular proteinase, obesity (abst) 674
high glucose, GF gene, human MC (abst) 693
intensive therapy 1703
L-arginine, vascular function (abst) 352
lipid profile (abst) 985
lipoprotein(a) serum levels (abst) 357
plasma lipids, ACE inhibitors 907
progression 231, 1781
renal TGF-f3, decorin mRNA (abst) 678
TGF-f3 production, cultured MC (abst) 673
Diadenosine polyphosphates
membrane voltage, MC (abst) 984
Na/H exchange, ADH, Ang II, CCD (abst) 999
Dialysate
AGE products, in vitro 1768
amino acid-based, malnourished CAPD patients 1148
CA125, transport kinetics (abst) 707
calcium, zero solutions, CAPD (abst) 369
commercial, TNFa mRNA, NF-kB DNA activity 1537
complement in, children, CAPD (abst) 705
endotoxin concentration in 356
one-line method, HD (abst) 970
protein losses, reused dialyzers 573
Dialysis. See also Continuous ambulatory peritoneal
dialysis (CAPD); Hemodialysis; Peritoneal dialysis
bone disease, PTH response 1434
congestive heart failure in 884
delivery, URR accuracy and Kt/V 319
Eastern Germany (1993)/GDR (1989) (abst) 1002
end-dialysis Na plasma water concentration (abst) 367
LDL metabolism, uremia 1732
new test for NO production (abst) 365
rHuIGF-1 impaired metabolic response 876
rHuIGF-1 pharmacokinetics 869
survival, diabetic/non-diabetic patients (abst) 981
Dialyzers
AMBIO, compatibility compared (abst) 966
differing membranes, ischemic ARF (abst) 985
elution technique, biocompatibility (abst) 1218
reuse and protein loss 573
Dietary. See also Salt
fatty acids, CsA therapy, GFR 611
protein, hypertension, PKD (abst) 973
protein, renal effects, early CRF (abst) 353
urinary protein concentration, health and CRF 7
Digoxin intoxication, HD (abst) 1484
Subject Index: VoL 47 1883
Dinucleotides, activate phospholipase C via AP4A
receptors, MC (abst) 1007
Dipyridamole and DN (abst) 678
Distal acid-base transport, Nephrology Forum 333
Diuresis
organic osmolytes, urine concentration (abst) 664
papillary pH gradient, CD urine, vasa recta (abst).. 681, 987
DNA fragmentation, hypoxia, TAL, kidneys 1806
DNA synthesis, tubular salt load 1615
Donor kidneys
Alport syndrome carriers as living donors (abst) 371
anti-HCV positive donors 236
living donor transplantation (abst) 360
non-immunologic factors (abst) 1005
pediatric, age-matching (abst) 996
plasma/urine ET-1, living related donors/recipients
(abst) 1008
Dopa, i.v., renal hemodynamics, normotensive ADPKD
(abst) 1218
Dopamine
excretion, post-HLA identical transplant (abst) 708
PGE2 production, ET (abst) 973
Duplex sonography, essential hypertension (abst) 986
E
E-selectin, Wegener's granulomatosis, SLE (abst) 989
ECTO-5'-nucleotidase (5'-NU), dual modulation (abst)... 699
Ectoenzymes, EC expression, signal transduction (abst) . . . 669
Elderly
antihypertensives, effects (abst) 962
antihypertensives, microalbuminuria (abst) 962
coronary risk assessment, pre-transplant (abst) 368
Electrophoresis, urine, interstitial nephritis (abst) 988
Embryogenesis, human kidney, GATA-3 gene expression. 1597
Embryonic ureteric bud cell expression (abst) 661
Enalapril
compared, nifedipine, BP, renal response, ET (abst)... 1216
erythrocytosis, post-transplant (abst) 361
End-dialysis Na plasma water concentration (abst) 367
End-stage renal disease (ESRD)
aluminum hydroxide, serum Al (abst) 354
cardiovascular disease 186
DN (abst) 988
HD and cardiovascular rhythms 1443
hyperhydration, arterial vessel walls (abst) 964
LPS-induced IL-1f3 production/secretion 1158
registry program, HITEL Closed User Group program
(abst) 355
Endocrine function
ischemic kidney (abst) 666
sino-carotid denervation, ANP (abst) 683
Endocytosis
aprotinin, PT gp330 binds/mediates (abst) 679
inhibition by specific antibodies (abst) 659
transcytosis, albumin gold, peritoneal mesothelium. ... 1274
Endothelial cells
400 kD laminin chains expression (abst) 697
dysfunction, EH (abst) 1000
dysfunction, microalbuminuria, IDDM (abst) 1223
TNF, ligand passing between receptors (abst) 677
tyrosine kinases, PDGF, angiogenesis (abst) 660
vascular, hemodynamic flow, NO synthesis (abst) 695
VEGF, expression and receptors (abst) 660
verocytotoxin receptor Gb3 induction (abst) 705
Endothelin
ACEi, prevent RF/death 1319
Ang II, endothelial mitogenic response (abst) 687
cortical/juxtamedullary renal vasculature (abst) 684
crush syndrome therapy (abst) 1483
human renal response, BP, enalapril, nifedipine (abst) . 1216
NO, gentamicin, MC activation (abst) 685
PGE2 production, dopamine (abst) 973
plasma, desferrioxamine, HD (abst) 356
renal function 795
renin secretion, juxtaglomerular cells (abst) 669
urinary, post-liver transplant 1426
Endothelin-1 (ET-1)
CsA, cell-cell interaction (abst) 670
endotoxin, glomerular resistance (abst) 676
fibrinolysis, prostaglandins, ARF (abst) 996
induces mesangial cell COX-2 53
NO system, ischemic/reperfusion injury (abst) 677
plasma/urine, before/after uninephrectomy (abst) 1008
plasma/urine, living related donors/recipients (abst) . . . 1008
receptor subtypes, cirrhosis (abst) 976
renal function, L-arginine (abst) 666
renal function, NO stimulation (abst) 707
renin release inhibition, juxtaglomerular cells (abst) . . . . 985
role in AIPKiiI (abst) 995
tubular regeneration (abst) 693
urodilatin, renal microcirculation (abst) 1009
Endothelin A (ETA) receptor antagonist
expression in kidneys, SHR (abst) 976
lupus nephritis 481
Endothelium-dependent forearm vasodilation, CsA
(abst) 1221
Endothelium-derived relaxing factor (EDRF), renal
microvessel vasodilation (abst) 684
Endotoxin
concentration in dialysate (abst) 356
glomerular resistance (abst) 676
vasoconstriction, preglomerular juxtamedullary vessels
(abst) 1216
Engelbreth-Holm-Swarm (EHS) experimental GN 404
Epidermal growth factor (EGF)
aminopeptidase N, 5'-NU, glomerular MC (abst) 699
calcium channel blocker, ischemic renal injury (abst) . . . 343
receptor, CPK mouse kidney 490
receptor, tyrosine kinase activity 774
TGF-/3, neutral endopeptidase, VSMC (abst) 665
Epithelial cells
abnormal transport by, PKD and 720
Ca influx (abst) 972
Cl transport inhibitors 722
determinants of polarity 724
differentiation in ADPKD 716
distinctive adherence of E. coli (abst) 688
ectoenzymes, signal transduction (abst) 669
exogenous Na/K-ATPase 0-subunit (abst) 680
generate metalloproteinases 1682
GP280 and GP330 expression, endocytosis (abst) 659
IL-2ra, IL-lcw, INF (abst) 677
IL-8, INF-y, IL-la, TNF-a (abst) 704
maturation, solute transport mechanisms 721
MCP-1, IL-la, TNF-a (abst) 705
membrane glycoprotein localized, PAN nephrosis
(abst) 689
molecular regulation, IL-8 production (abst) 694
1,25-D3 increases ICAM-1 (abst) 968
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PKD, abnormal regulation of cell growth 715
polarized ion transport (abst) 1001
polarized molecular transport abnormalities, PKD 724
polarized surface, lipids, proteins (abst) 658
pro-inflammatory mechanisms (abst) 677
produce enzymes, regulate ECM turnover (abst) 673
renal, membrane surface of (abst) 679
Epstein Barr virus (EBV)
malignant lymphoma, post-transplant (abst) 980
reactivated post-transplant, sero-diagnosis (abst) 1006
Erythrocytes
accumulate S-adenosylhomocysteine, uremia 247
Ca transport, hypercalciuria (abst) 363
dysmorphic, histopathology of ON (abst) 972
Erythrocytosis
enalapril, post-transplant (abst) 361
post-transplant predisposition (abst) 975
Erythropoietin (EPO)
acute renal failure (abst) 974
with low dose i.v. iron, HD (abst) 998
mRNA, oxygen-dependent expression, kidney (abst).... 694
nifedipine, RAS effects (abst) 683
response, hippuric acid, HD (abst) 984
rHuEPO, LH kinetics/biopotency, men on HD (abst).. 1004
rHuEPO, stimulates angiogenesis 740
Escherichia coli
adherence, cultured human tubular EC (abst)
host-specific uropathogenic virulence (abst)
megalocytic interstitial nephritis (abst)
verocytotoxin-producing, hemolytic uremic syndrome
(abst) 1222
Essential hypertension (EH)
ambulatory BP monitoring, salt intake (abst) 978
AT-i receptor antagonist SR 47436 (abst) 1216
DDAVP vasodilator effects (abst) 706
duplex sonography and age (abst) 986
human endothelium function (abst) 1000
hyperfiltration, salt intake (abst) 366
Na intake, albuminuria (abst) 992
renal/systemic response to RAS (abst) 703
renin-inhibition, natriuresis (abst) 1217
Essential mixed cryoglobulinemia (EMC)
HCV antigen immune response, HLA typing (abst) .... 367
nephritis, long-term survival 618
Evening primrose oil, GFR, CsA 611
Exercise-induced K changes, CRF (abst) 969
Exit-site infections
local antibiotic treatment (abst) 982
sulcus fluid flow rate, PD (abst) 994
Extracellular matrix (ECM)
abnormalities of, PKD and 725
AGE, ECM gene overexpression, DM, GS 49:S-55
basement membrane structure 49:S-4
cell-cell cross-talk, interstitial renal fibrosis 49:S-48
cell specific regulation, TGF-/3 (abst) 363
crinopexy, extracellular GF regulation 49:S-15
degradation by PA/plasmin/MMP-2 cascade 1039
GS progression and 49:S-39
models of nephron reduction 49:S-51
proteinases, human renal fibroblasts (abst) 990
remodeling, metalloproteinases, PAs 49:S-12
renal disease progression, chemokines 49:S-44
TGF-/3 mediates GS 49:S-59
TGF-f3 overview 49:S-19
transmembrane signaling 49:S-8
turnover regulation, fibroblast enzymes, EC (abst) 673
Extracellular nucleotides
Ca, cortical TAL, Henle's loop (abst) 700
modulate renal transport 1500
renal handling (abst) 699
Extracellular osmolality, taurine efflux (abst) 678
ExtracorpOreal circulation
acute opiate intoxication (abst) 1007
for heart-lung bypass, ARE (abst) 343
simultaneous adsorption/filtration (abst) 971
Extracorporeal shock wave lithotripsy (ESWL) (abst) 345
F
Factor B, MC synthesis, cytokines, MHC antigens (abst) . . 671
Familial hypomagnesemia 1419
Fatty acids
dietary supplementation, CsA therapy, GFR 611
polyunsaturated free, antidiuresis, vasopressin (abst). . . . 687
Fcy receptor III (CD16), human glomerular MC (abst)... 670
Felodipine derivative, hypoxic PT cell injury (abst) 702
Femoral head necrosis, post-transplant (abst) 984
Fibrinogen serum levels, atherosclerosis, CAPD (abst). . . . 965
Fibrinolysis
peritoneal, mesothelial cells, CAPD (abst) 997
prostaglandin synthesis, ET-1, ARF (abst) 996
688 therapy, renal vein thrombosis, NS (abst) 1483
973 Fibroblast growth factor (FGF)
986 PDGF, IL-1/3, NOS, MC (abst) 695
podocyte mitosis, cell division (abst) 689
podocytes, membranous nephropathy (abst) 677
Fibroblasts
ECM-degrading proteinases/inhibitors (abst) 990
enzymes, regulate ECM turnover (abst) 673
IL-i 837
IL-i, IL-6, IL-8 845
interstitial renal fibrosis (abst) 673
molecular biology of origins (abst) 1002
transdifferentiation, renal fibrogenesis (abst) 1002
Fibromuscular dysplasia causes RAS (abst) 1219
Fibronectin
cytoprotection by silibinin (abst) 673
isoforms, anti-Thy-i nephritis (abst) 698
production, cytokines, MC (abst) 673
5HTia receptor agonist (Flesinoxan) (abst) 668
5 '-nucleotidase (5 '-NU)
dual modulation (abst) 699
upregulation, EGF, human MC (abst) 699
FK506
24-hour BP monitoring, CsA (abst) 977
metabolic changes, post-transplant (abst) 977
renal function, serum electrolytes (abst) 977
salvage, OKT3 resistant rejection (abst) 975
urinary ET, post-liver transplant 1426
Flesinoxan, renal function (abst) 668
Focal segmental glomerulosclerosis (FSGS)
clinicopathology, adults (abst) 348
distribution of lesions, adults/children 1690
early morphological changes (abst) 348
podocytes, adhesive phenotype (abst) 689
prolonged NOS blockade (abst) 696
Forearm vasculature
hypertension, muscarinic receptors (abst) 705
hypertension, vasodilation, CsA (abst) 1221
400 kD laminin chains, ET cells (abst) 697
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Furosemide
Na and Cl-dependent taurine reabsorption (abst) 997
tubular hypertrophy, IGF-1 and IGFBP-1 818
tubular site of action (abst) 682
G
G-proteins, organic osmolyte efflux, CD cells (abst) 996
Gamma-globulin, i.v., renal effect (abst) 351
GATA-3 gene expression, kidney embryogenesis 1597
Genetics
ACE gene and DN 1176
adenovirus-mediated gene transfer 322
Ang2 receptor mRNA 1095
antisense angiotensinogen transgenic mice 1638
antisense oligonucleotides, organ development (abst)... 693
biphasic TNF-a in MRL-lpr mice 122
COL4A3 mutation, Alport syndrome 1199
GATA-3 expression, human kidney embryogenesis.... 1597
Gitelman's syndrome 547
Henoch-Schonlein (abst) 364
HLA-DRB1, PKD-1 gene analysis, adult PKD (abst) ... 996
human renal development (abst) 661
localization of Mn-SOD mRNA, nephron 536
malignant hypertension model 529
mutation, hereditary nephrogenic DI (abst)... 344, 364, 991
new mouse PKD mutant 552
novel gene products, renal organogenesis (abst) 986
polycystic kidney disease (PKD) 728
prenatal diagnosis of Alport syndrome 327
renal genes, kidney differentiation/disease (abst) 669
Rf-1 gene identification (abst) 702
Senior-Loken syndrome (abst) 662
targeted oncogenesis, renal cell lines 388
transferrin gene expression 1068
WiIm's tumor protein expression (abst) 661
Gentamicin
hypercalciuria, nephron site (abst) 667
MC activation, ET, NO (abst) 685
PAF in mesangial cells 1346
Gitelman's syndrome
calcium absorption (abst) 364
genetics 547
Glomerular basement membrane (GBM)
anti-GBM Ab (abst) 350
antibody deposits, immune complexes (abst) 1006
heparan sulfate changes, DN (abst) 701
heparan sulfate staining, lupus nephritis (abst) 701
Glomerular capillaries
albumin binding to wall 1031
morphometry, reflux nephropathy, children 1108
Glomerular cells
human epithelial, metalloproteinases 1682
molecular regulation, IL-8 production (abst) 694
Glomerular filtration rate (GFR)
allografts, pre/post-transpiant (abst) 360
cystatin C as marker 312
dietary fatty acids, CsA therapy 611
elevation, glucagon, cAMP, urea (abst) 685
endotoxin, hemodynamic resistance (abst) 676
inulin clearance, without urine collection (abst) 993
long-term antihypertensive therapy, DN 1726
Glomerular function
analysis of biopsy cases (abst) 346
blood flow control and NO (abst) 676
cAMP-dependent protein kinase (abst) 688
CsA, azathioprine (abst) 1221
Glomerular hypertrophy
GS in proteinuric rats (abst) 691
hyperplasia, isolated glomeruli (abst) 691
Glomerular injury, ACEi, mesangial volume (abst) 676
Glomerular labeling, nephrogenesis (abst) 661
Glomerular permeability
ANP, natriuresis, albuminuria, NS (abst) 993
MCD, vasoactive human plasma factor (abst) 1218
PGE1, proteinuria, renal hemodynamics, GN (abst) ... 1007
Glomerular proteinase activity, DM, obesity (abst) 674
Glomerular proteolysis, protein synthesis, GS (abst) 1009
Glomerulonephritis
adults, analysis of biopsy cases (abst) 346
ANCA-associated 193
anti-MPO, ischemia/reperfusion injury 1121
apoptosis (abst) 657
bacterial LPS-induced, INF-y (abst) 974
crescent formation, anti-GBM Ab (abst) 350
crescentic, /3 /33 integrins, ICAM-1, VCAM-i
counter-receptors (abst) 370
crescentic, IL-ira halts established 1303
dysmorphic erythrocytes, histopathology (abst) 972
EHS experimental 404
EMC, long-term survival 618
ICAM-1, /31 integrin, MC (abst) 352
IgA mesangial, induced by dextran (abst) 691
INF-c therapy, HBV (bst) 349
L-arginine, proteinuria, hypertension (abst) 1007
lipoxin A4 synthesis . 1295
membranous, urinary CD59, SC5b-9 and cytokines.... 1403
methicillin-resistant S. aureus infection 207
ornithine metabolism (abst) 678
PGE1, proteinuria, renal hemodynamics (abst) 1007
proliferative, apoptosis in 114
proliferative, MC apoptosis (abst) 688
secondary membranoproliferative, Nephrology Forum .. 643
undifferentiated connective tissue disease (abst) 987
Glomerulosclerosis
AGEs induce ECM gene overexpression, DM 49:S-55
Ang II modulates PDGF 131
collagen, collagenase mRNAs, progression 49:S-39
de novo diabetic GS, post-transplant (abst) 970
differential expression, collagen subchains (abst) 698
FGF, podocytes, membranous nephropathy (abst) 677
FSGS, adults, clinicopathology (abst) 348
FSGS, adults/children 1690
FSGS, early morphological changes (abst) 348
FSGS, pódocytes, adhesive phenotype (abst) 689
FSGS, prolonged NOS blockade (abst) 696
glomerular hypertrophy, proteinuria (abst) 691
glomerular proteolysis, protein synthesis (abst) 1009
MC collagen, insulin 25
MC growth abnormalities 106
PAN, MCP-I, TGF-(3 (abst) 691
podocyte injury (abst) 986
TGF-/3 mediates 49:S-59
uninephrectomized female analbuminemic rats 442
Glomerulus
adenosine-hypersensitivity, low-Na rats (abst) 686
cationized Ig aggregates (abst) 688
charge selectivity, horseradish peroxidase 1630
dextran sulfate uptake, ultrafiltration 945
EC membrane glycoprotein, PAN nephrosis (abst) 689
fibronectin isoforms, anti-Thy-i nephritis (abst) 698
lipid peroxidation, high glucose (abst) 351
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regulation, iNOS expression 500
scierosed, adults vs. children 1690
soluble/particulate guanylyl cyclase systems (abst) 696
transplantation, genetically-engineered MC (abst) 689
ultrastructural changes, microalbuminuria, DM (abst)... 674
vasotocin receptors, phosphoinositidase C (abst) 687
Glucagon, GFR elevation, cAMP, urea (abst) 685
Glucocorticoids
K transport, Henle's loop 802
Na/K-ATPase gene transcription (abst) 680
renal NaHCO3 cotransporter 1669
Glucose
high, ICAM-1, f31 integrin, MC (abst) 352
high, lipid peroxidation, isolated glomeruli (abst) 351
high, PKC isoforms, VSMC 1057
MC, GF gene expression (abst) 693
Glutamine
exogenous, tubular cell growth 299
metabolism, regulation by OK cells 96
Glycine-induced hyponatremia, post-prostatectomy 262
Glycoprotein, 43 dDal membrane, PAN nephrosis (abst).. 689
Glycosaminoglycans (GAG)
suiphated, proteinuria, overt nephropathy (abst) 1224
synthesized, MC, compared proteoglycans (abst) 690
Glycosylation
abnormal IgA, integrin expression on MC 365
altered IgA, IgA nephropathy (abst) 365
Goodpasture's syndrome
autoantibody-antigen binding (abst) 698
autoreactive T-cell clones (abst) 690
EHS type IV collagen, GN 404
positive circulating anti-GBM antibodies (abst) 350
gp330
binds/mediates endocytosis of aprotinin (abst) 679
cloning/sequencing of cDNA coding (abst) 689
Granulocyte inhibitory protein (GIP), uremic toxicity
(abst) 672
Granulocytopenia, biphasic, post-OKT3 (abst) 1218
Granzyme A, B proteins, cytotoxic lymphocytes, rejection .. 70
Growth factors
autocrine regulation human MC, cytokines (abst) 692
in cell proliferation 719
crinopexy, extracellular regulation 49:S-15
deprivation, proliferative GN (abst) 688
high glucose, gene expression, human MC (abst) 693
Growth hormones
IGF-1 in ARF 1658
IGF-1 mRNA in GH-treated uremic bone 1374
Guanidino compounds, renal insufficiency 464
Guanylyl cyclase systems, in glomeruli (abst) 696
H
Hantavirus nephropathy (abst) 707
Heat disinfection, membranes 638
Heat shock proteins (HSP)
HSP 70, mRNA expression, PT cells (abst) 986
localization, kidney (abst) 990
renal ischemic injury 1752
Heavy metal intoxication
early urinary detection (abst) 971
rBAT-induced amino acid transport 1677
Heme-induced cytoresistance 1336
Heme protein-mediated renal injury, 21-aminosteroids.... 592
Hemodialysis. See also Dialysate; Membranes,
hemodialysis
ANP, brain and C-type natriuretic peptides (abst)
antiphospholipid antibodies (abst)
bacterial infection, HCV, HBsAg, CD14 (abst)
BIA evaluation, body fluid composition (abst)
bone disease, PTH response
bone mass reduction dynamics (abst)
[Ca2I1 verapamil, PMNL function
calcium-free, hypercalcemia management (abst)
cardiovascular rhythms, ESRD
coronary artery calcifications (abst)
coronary risk factors (abst)
dermal angiopathy
desferrioxamine, plasma endothelin (abst) 356
dialyzer elution technique (abst) 1218
digoxin intoxication (abst) 1484
dose, nutritional parameters (abst) 970
electric bio-impedance (abst) 987
EPO with low dose i.v. iron (abst) 998
HCV nosocomial infection 911
high serum levels soluble CD14 (abst) 973
hippuric acid concentration, EPO (abst) 984
interferon therapy, HCV 1412
LH kinetics/biopotency, rHuEPO, men (abst) 1004
low turnover osteopathy (abst) 1000
math model for f32-M deposits 1453
metabolic acidosis anion gap patterns (abst) 354
monokine production 559
morbidity/mortality factors (abst) 357
mortality time course, Uruguay 1722
nutritional comparison, CAPD (abst) 358
one-compartment (blood) UKM (abst) 970
one-line method (abst) 970
pantoprazole, pharmacokinetics (abst) 984
Permcath complications (abst) 977
polyamines in RBC and plasma (abst) 972
post-contrast media application (abst) 988
removal, NOS-blocking compounds (abst) 363
serum K concentration, hyperkalemia (abst) 355
serum phosphate, post-parathyroidectomy (abst) 1000
serum soluble HLA-I antigen levels (abst) 359
simultaneous adsorption/filtration (abst) 971
single/double pump, one/two needles (abst) 1482
staphylococcus-effective prophylaxis, CRIs (abst) 994
tuberculosis manifestations (abst) 359
UV irradiation, disinfection of water (abst) 1481
vascular access, clotting, SLE (abst) $6
vascular access, coagulation abnormalities (abst) $6
vascular access, measurement methods (abst) 356
vascular access, seroma, PTFE grafts (abst) $6
vascular access, thrombosis 1364
zinc protoporphyrin, endogenous iron (abst) 964
Hemofiltration, continuous, ARF (abst) 989
Hemoglobin, carbamylated, index of uremia (abst) 1219
Hemolytic uremic syndrome
clinical study (abst) 342
verocytotoxin-producing E. coli (abst) 1222
Hemoperfusion
paraquat intoxication (abst) 359
propafenone intoxication (abst) 988
Hemorrhage, pulmonary, ANCA-positive vasculitis (abst) . 365
Hemorrhagic fever with renal syndrome (HFRS)
adhesion molecules (abst) 350
NO role (abst) 353
Henoch-Schonlein
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susceptibility, HLA-DRBI gene analysis (abst) 364
Heparan sulfate proteoglycans
Mg II, human MC (abst) 701
GBM, lupus nephritis (abst) 701
GBM changes, DN (abst) 701
perlecan modulates MC (abst) 690
Heparin
dosages/targets, neuropathy (abst) 689
extracorporeal LDL precipitation (HELP) (abst) 999
lowers blood pressure 1017
thrombocytopenia, anaphylaxis, post-
parathyroidectomy (abst) 1003
Hepatitis, chronic viral and CRF 1231
Hepatitis B virus (HBV)
CD14, HCV, bacterial infections, HD (abst) 999
East German dialysis centers (1989-1993) (abst) 1003
INF-a therapy, GN (abst) 349
membranous nephropathy, INF-a 225
post-transplantation (abst) 1001
vaccine non-responders, rIL-2, uremia (abst) 1483
Hepatitis C virus (HCV)
anti-HCV antibodies, cryoglobulinemia (abst) 367
anti-HCV positive allograft recipients, HBsAg (abst) . . . 361
anti-HCV positive donors 236
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post-transplantation (abst) 1001
prevalence, mode of transmission (abst) 357
Hepatocytes
growth factor as a renotrophic factor 718
metabolism, CRF 1522
Heymann nephritis
active, complement C6 1604
eDNA coding for gp330 (abst) 689
receptor-associated 39/45 kD protein 432
renal injury, NOS inhibition (abst) 692
High density lipoprotein (HDL), RA dilation (abst) 684
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allograft recipients, living-related donors (abst) 361
altered glycosylation of IgA (abst) 365
clinical perspectives 377
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familial (abst) 367
ICAM-1, MC, cytokines, MNC (abst) 352
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heme protein-mediated, 21-aminosteroids 592
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ischemic, calcium channel blocker, c-fos, EGF (abst) . . . 343
ischemic, heat shock proteins 1752
ischemic, heat shock proteins (abst) 986
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reperfusion, ET-1, NO system (abst) 677
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reperfusion, ischemia, ET-1, NO (abst) 677
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Insulin-like growth factor-i (IGF-1)
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renal growth hormone, ARF 1658
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MC expression, IgA modulates (abst) 365
Intercellular adhesion molecule-i (ICAM-1)
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hemorrhagic fever with renal syndrome (abst) 350
human allograft rejection, VCAM-1 1383
interstitial nephrosclerosis, MCP-1 (abst) 692
leukocyte, renal vasculitis, IL-la (abst) 672
leukocyte, renal vasculitis, VCAM-i (abst) 363
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MC, f31 integrin, high glucose (abst) 352
MC, cytokines, MNC, IgA nephropathy (abst) 352
1,25-D3 increases, human TEC (abst) 968
Wegener's granulomatosis, SLE (abst) 989
Interferon-a (INF-a)
therapy, HBV-associated GN (abst) 349
therapy, HBV membranous nephropathy 225
therapy, HCV, hemodialysis 1412
upregulation, IL-2ra, proximal ET (abst) 677
Interferon-y (INF-y)
bacterial polysaccharide GN (abst) 974
mesangial proliferative nephritis 62
NS, children, CsA, steroids, IgE-rIl (abst) 346
PTEC production human IL-8 (abst) 704
Interleukin-1 (IL-i)
chronic allograft rejection (abst) 361
cyclooxygenases, prostacyclin, TxA2 MC (abst) 686
human kidney fibroblasts 837
IL-8, IL-6 in human MC, cAMP (abst) 687
receptor antagonist halts crescentic GN 1303
synthesis, IL-6, IL-8 production, fibroblasts 845
Interleukin-la (IL-la)
leukocyte, renal vasculitis, ICAM-1, VCAM-1 (abst). . . . 672
PTEC production, IL-8 (abst) 704
PTEC production, MCP-1 (abst) 705
Interleukin-1 13 (IL-iJ3)
bone disease, f32-M, prostaglandins 587
induced NOS, dexamethasone, cAMP, MC (abst) 992
induced NOS, FGF, PDGF, MC (abst) 695
lipopolysaccharide-induced, mononuclear cells, ESRD . 1158
NOS expression by NO in MC (abst) 990
tyrosine phosphorylation, COX II expression 1354
Interleukin-2 (IL-2)
receptor, anti-IL-2R MoAb, rejection (abst) 708
receptor, proximal tubular EC (abst) 677
rIL-2, uremia, HBV vaccine non-responders (abst). . . . 1483
Interleukin-6 (IL-6)
LPS and cAMP induce gene expression (abst) 694
peritoneal mesothelial cell synthesis 282
production, chronic HD patients 559
production, cultured kidney fibroblasts 845
Interleukin-8 (IL-8)
molecular regulation, human glomerular EC (abst) 694
production, cultured kidney fibroblasts 845
PTEC, IL-la, INF-y, TNF-a (abst) 704
Interleukin-lO (IL-b), production, chronic HD patients. . . 559
Interstitial cell culture, Na transport, CD cells (abst) 973
Interstitial nephritis
megalocytic, E. coli bacteremia (abst) 986
urine electrophoresis (abst) 988
Interstitial nephrosclerosis, pathogenesis (abst) 692
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Intrarenal apoptosis from hypoxia 1806
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Ion transport
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lopentol, pharmacokinetics with RI (abst) 988
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transferrin gene expression 1068
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calcium channel blockers, Na/K-ATPase (abst) 345
DNA fragmentation, TAL, kidneys 1806
endocrine function, ischemic kidney (abst) 666
ET-1, NO system, reperfusion injury (abst) 677
heat shock proteins do not prevent injury 1752
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reperfusion injury, anti-MPO GN 1121
21-aminosteroid effects, reperfusion injury (abst) 1222
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ET-1 inhibits renin secretion (abst) 985
ET effects, renin secretion (abst) 669
RAS, NOS distribution (abst) 670, 964
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K
conductance of PT, cytosolic pH regulation (abst)




brain, expression patterns, transfected in MDCK cells
(abst)
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K deprivation, salt restriction, calciuria
K loading, PT, loop of Henle Na, K reabsorption (abst)
K permeability disorders, chronic RI (abst)
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K serum concentration, hyperkalemia, HD (abst)
K transport
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Kallikrein, HCO3 excretion regulation (abst)
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CsA toxicity, modulated by NO 1507
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Lactate-buffered CAPD fluids, mesothelial cell function. .. 282
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infiltration, renal vasculitis, ICAM-1, VCAM-1, IL-la
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profile improvement, polyamide membrane HD (abst) . 1485
sorting to polarized epithelial surface (abst) 658
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Lipopolysaccharides
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macrophages, dialysate, TNFa mRNA, NF-kB activity . 1537
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endothelium-dependent RA dilation, HDL (abst) 684
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Lipoproteins
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Liver transplantation, urinary endothelin, CsA, FK506. . . 1426
LLC-PK1 cells
mercury toxicity 395
NH4C1-induced hypertrophy, lysosomal cysteine
proteinases (abst) 1003
TGF-pl, proteinase activity (abst) 1003
transport system, cisplatin effects (abst) 343
ultrastructure and water transport (abst) 663
Loop diuretics, torasemide (abst) 992
Loop of Henle
extracellular NaC1 modulates adenosine (abst) 681
extracellular nucleotides, Ca, cortical TAL (abst) 700
furosemide, taurine reabsorption (abst) 997
glucocorticoids, K transport 802
medullary hypotonicity, HCO3 transport (abst) 667
Na, K reabsorption with K loading (abst) 667
Na reabsorption, measurement methods (abst) 667
Na transport in ATL 789
Lovastatin, PDGF-induced DNA synthesis, MC (abst).... 351
Low blood flow method, vascular access recirculation
measurement (abst) 356
Low density lipoproteins (LDL)
apheresis, lipid peroxidation during, HELP (abst) 999
Lp(a), renin release of JG cells 45
stimulates MC proteoglycans (abst) 690
Low-density lipoproteins (LDL)
metabolism, uremia, dialysis 1732
nephrotic dyslipidemia 579
lpr gene, biphasic TNF-a in MRL-lpr mice 122
Lung transplantation, renal function after (abst) 704
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ETA receptor antagonist 481
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Lymphocytes
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LPS-stimulated, dialysate, TNFa mRNA, NF-kB
activity 1537
peritoneal, characterization, PD (abst) 1481
Macula densa cells
apical sodium proton exchange 746
Na:2Cl:K cotransport, luminal chloride 752
Magnesium
renin, Na excretion, relative heart weight (abst) 995
transport, cell membranes, RI (abst) 983
Major histocompatibility complex (MHC)
alleles, systemic vasculitis 294
antigens, complement factors, MC, cytokines (abst) . . . . 671
Malignant hypertension, genetic model 529
Matrix metalloproteinases (MMP)
expression and TIMP, ARPKD (abst) 659
generated by human glomerular EC 1682
PA/plasmin cascade, ECM degradation 1039
remodel ECM, plasminogen activators 49:S-12
Maturation arrest hypothesis, PKD 715
MDCK cells
CD intercalated cell properties (abst) 679
cell volume during migration (abst) 697
mercury toxicity 395
Medullary CD, acid-base transport, Nephrology Forum... 333
Medullary hypotonicity, HCO3 transport (abst) 667
Medullary interstitium, NaCl, prostaglandins (abst) 668
Medullary nephrocalcinosis, sonography, adults (abst) .... 995
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MELAS and renal failure (abst) 1219
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AMBIO dialyzer biocompatibility (abst) 966
bacterial product transfer 603
f32-M adsorption (abst) 356
differing, ischemic ARF recovery (abst) 985
drug kinetics, PAN membrane (abst) 982
interaction, adhesion proteins 1115
oxygen radicals, biocompatibility (abst) 995
polyamide, lipid profiles (abst) 1485
polysulphone dialyzers, heat disinfection 638
polysulphone dialyzers, reuse, protein loss 573
Membranoproliferative GN, secondary, Nephrology
Forum 643
Membranous glomerulonephritis
undifferentiated connective tissue disease (abst) 987
urinary CD59, SC5b-9 and cytokines 1403
Membranous nephropathy
clinical review (abst) 349
FGF, podocyte injury (abst) 677
HBV, INFa therapy 225
idiopathic, urinary excretion J32-M (abst) 1218
progressive, cyclosporine trial 1130
Mercury toxicity in kidney cells 395
Mesangial cells
adult proliferation, verapamil (abst) 991
ANP, growth suppression, TGF-j3 (abst) 692
apoptosis (abst) 688
ATP, phospholipase C, c-fos, P2u-receptors (abst) 669
autocrine regulation, cytokines, GF (abst) 692
biosynthesis, C3 829
C-type natriuretic peptide receptors (abst) 682
Ca-dependent Cl conductance (abst) 991
CD44 shedding, neutrophil proteases (abst) 671
cholesterol loading, Lp(a) (abst) 989
collagen, insulin, nodular sclerosis 25
complement factors, cytokines, MHC antigen (abst) . . . . 671
cytokines modulate fibronectin (abst) 673
diadenosines, membrane voltage (abst) 984
ectoenzyme expression, signal transduction (abst) 669
EGF, aminopeptidase N, 5'-NU (abst) 699
ET-1 induces cyclooxygenase-Il 53
extracellular ATP, UTP, membrane voltage (abst) 700
Fey receptor III (CD16) (abst) 670
FGF, PDGF, IL-1/3 induced NOS (abst) 695
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gentamicin, ET, NO (abst) 685
gentamicin, PAF 1346
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integrins, IgA modulatory role (abst) 365
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lovastatin, PDGF (abst) 351
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Na/myo-inositol cotransport 473
NOS expression, IL-1/3, MC (abst) 990
proliferation, dinucleotides, phospholipase C, AP4A
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receptor-mediated binding, nucleosomes 1258
regulation of iNOS expression 500
serotonin, phospholipase D (abst) 688
smooth muscle a-actin, IgA nephropathy (abst) 364
somatostatin, intracellular cGMP synthesis (abst) 666
TGF-/3 production, high glucose (abst) 673
tyrosine phosphorylation, PDGF (abst) 687
U-937 monocyte adhesion (abst) 660
Mesangial proliferative nephritis, INF-y 62
Mesothelial cells
endocytosis, transcytosis of albumin gold 1274
lactate-buffered CAPD fluids 282
peritoneal fibrinolytic system, CAPD (abst) 997
Metabolic acidosis
anion gap patterns, HD (abst) 354
chronic renal failure (abst) 355
hyperkalemia, NaHCO3 insulin in glucose (abst) 355
osteoblastic intracellular pH and Ca 1790
prolonged, chronic renal injury (abst) 691
Metabolic risk factors, post-transplant (abst) 979, 980
Methicillin-resistant S. aureus, GN 207
Methylmalonic acid serum concentration, uremia (abst)... 964
Methyiprenisolone pulse therapy, steroid-resistant NS
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Microalbuminuria
antihypertensive therapy (abst) 962
elderly, antihypertensive therapy (abst) 962
endothelial dysfunction, IDDM (abst) 1223
glomerular changes, DM (abst) 674
high serum prorenin, IDDM (abst) 1224
non-diabetic hypertensives, other concomitant diseases
(abst) 962
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injury (abst) 962
Microcytosis, aluminum-induced 164
Microform of PAN, Wegener's granulomatosis (abst). . . . 1000
Micropuncture
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Na reabsorption, Henle's loop (abst) 667
tubular site of action, furosemide (abst) 682
Microscopic polyarteritis, anti-MPO antibodies (abst) 368
Minimal change disease (MCD)
Ciq nephropathy (abst) 347
children (abst) 346
proteinuria pathogenesis (abst) 1218
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stroke-like episodes (MELAS), renal failure (abst) . . . . 1219
Monoclonal antibodies (MAB)
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anti-lymphocyte, fail to prevent rejection (abst) 1222
TN2O, interstitial renal fibrosis (abst) 673
Monoclonal gammopathy, immunotactoid-like
glomerulopathy, liver/bone marrow fibrillary deposits
(abst) 998
Monocyte chemoattractant protein-i (MCP-1)
GS, PAN, TGF-/3 (abst) 691
interstitial nephrosclerosis, ICAM-1 (abst) 692
PTEC production (abst) 705
Monocytes, U-937 cell line, MC adhesion (abst) 660
Monokines in HD patients 559
Mononuclear cells (MNC)
ICAM-1, MC, cytokines, IgA nephropathy (abst) 352
LPS-induced IL-1/3 production/secretion 1158
Moxonidine, urinary Na, renal hemodynamics (abst) 972
MRL-lpr mice, biphasic TNF-a 122
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Nat-coupled uptake, BBM fluidity, cisplatin 1048
Na excretion
magnesium, renin, relative heart weight (abst) 995
urinary, moxonidine, renal hemodynamics (abst) 972
Na/H exchange
ADH, Ang II, diadenosines, CCD (abst) 999
antiporter (NHE-1 isoform) in VSMC 78
isoforms, RT-PCR detection, outer medulla (abst) 674
macula densa cells 746
mammalian gene, structure/function (abst) 674
Na homeostasis, post-HLA identical transplant (abst) ... 708
Na/K-ATPase
calcium channel blockers, acute ischemic RF (abst) . . . . 345
exogenous 0-subunit expression, EC (abst) 680
gene transcription, glucocorticoids (abst) 680
lipid peroxidation, PT cells (abst) 663
neuropeptide Y, proinsulin C-peptide (abst) 678
phosphorylation, protein kinases (abst) 675
PKC phosphorylation, E1-E2 (abst) 696
pump recruitment, cell volume, CCD (abst) 659
Na/Li red cell countertransport, IgA nephropathy (abst) . . 366
Na/myo-inositol cotransport, MC 473
Na/P-cotransport system
acute up-regulation, proximal tubular (abst) 675
baculovirus-infected insect cells (abst) 662
electrophysiology, xenopus oocytes (abst) 662
molecular aspects in flounder (abst) 663
mRNA/protein level (abst) 662
sensitivity differences, PT (abst) 663
Na reabsorption
barium effect (abst) 663
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taurine dependent, furosemide (abst) 997
Na sensitivity, vascular compliance, hypertension 169
Na transport
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ICy immunoneutralization, ANP, renal function (abst) . 682
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Neonates, indomethacin, renal hemodynamics (abst) 342
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Heymann, complement C6 1604
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lupus, heparan sulfate staining, GBM (abst) 701
lupus, PAl-i expression 148
lupus, TXA2 synthase inhibition 1168
mesangial proliferative, INF-y 62
nephrotoxic, chemokines, leukocyte influx (abst) 660
nephrotoxic serum, anti-MPO antibodies 454
Nephrocalcinosis
familial hypomagnesemia, hypercalciuria 1419
medullary, sonography, adults (abst) 995
Nephronophthisis
osseus malformations (abst) 1008
retinitis pigmentosa (abst) 662
Nephrons
distal, NaC1 transport, DNA synthesis (abst) 680
experimental models of reduction 49:S-51
Mn-SOD mRNA localization 536
number, pre-transplantation (abst) 707
organic osmolytes along (abst) 679
single nephron albuminuria 1078
single nephron albuminuria (abst) 1217
Nephropathy. See also Diabetic nephropathy; IgA
nephropathy
analgesic, post-transplant, urothelial carcinoma (abst). . . 984
experimental, heparin dosages/targets (abst) 689
membranous, clinical review (abst) 349
membranous, FGF, podocytes (abst) 677
membranous, HBV, INFa 225
membranous, idiopathic, urinary 2-M (abst) 1218
membranous, progressive, cyclosporine 1130
reflux, children, glomerular morphometry 1108
rheumatoid arthritis (abst) 350
sulphated glycosaminoglycans, proteinuria (abst) 1224
Nephrosis
adriamycin, antiproteinuria, ACEi (abst) 1223
PAN, 43 dDal glycoprotein, in GEC (abst) 689
Nephrotic dyslipidemia, LDL metabolism 579
Nephrotic syndrome
adult, biopsy analysis (abst) 345
adults, fibrinolysis, renal vein thrombosis (abst) 1483
ANP, natriuresis, albuminuria, glomerular permeability
(abst) 993
bumetanide (abst) 354
Clq nephropathy (abst) 347
children, sonography (abst) 346
children, steroid-resistant, MP pulse therapy (abst) 348
children, steroid-responsive 1392
children, steroids, bone metabolism (abst) 347
children, steroids, CsA, INF-y, IgEr-Il (abst) 346
children, urinary f32-M, proteinuria (abst) 346
hypertriglyceridemia 566
idiopathic, uremia (abst) 348
Nephrotoxic nephritis
anti-MPO antibodies 454
chemokines, leukocyte influx (abst) 660
Nephrotoxicity
contrast media, ionic/nonionic 254
contrast media, N-acetyl-D-glucosaminidase (abst) . . . . 342
CsA, arginine, modulated by NO 1507
CsA, lipid peroxidation, vitamin E 927
CsA, membranous nephropathy 1130
cytoprotection, silibinin, SOD (abst) 971
Russell's viper venom 518
Netilmicin, PAN membrane, HD (abst) 982
Neuraminidase, kidney cellular infiltration 88
Neuropeptide Y, proinsulin C-peptide, Na/K-ATPase
(abst) 678
Neutral endopeptidase
TGF-f3, EGF, VSMC (abst) 665
urinary, and salt loading 855
Neutral horseradish peroxidase, charge selectivity 1630
Neutrophils
apoptosis, eDNA cell transfection, CD36 (abst) 671
cellular infiltration, neuraminidase 88
elastase, cathepsin G, CD43 shedding (abst) 672
lipoxin synthesis, GN 1295
pathogenesis, experimental vasculitis (abst) 672
NF-kB DNA-binding, commercial dialysate 1537
NH4C1, cellular hypertrophy, lysosomal cysteine
proteinases (abst) 1003
NHE-1 isoform (Na/H antiporter), VSMC 78
Nicardipine, compared to nifedipine (abst) 683
Nifedipine
compared, enalapril, BP, ET (abst) 1216
RAS effects, compared to nicardipine (abst) 683
RAS effects, erythropoietin (abst) 683
Nitrate in stable CAPD and peritonitis (abst) 1217
Nitrendipine, urinary enzymes, proteinuria, contrast
media (abst) 369
Nitric oxide (NO)
blockade, tubuloglomerular feedback (abst) 695
blockade induces FSGS (abst) 696
endothelial cells, CsA (abst) 670
ET, gentamicin activation, MC (abst) 685
ET-1, human renal function (abst) 707
ET-1, ischemia/reperfusion injury (abst) 677
glomerular blood flow control (abst) 676
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hemodynamic flow, vascular EC (abst) 695
hemorrhagic fever with renal syndrome (abst) 353
L-arginine, captopril, CRF 1515
modulates CsA toxicity, arginine 1507
production during dialysis (abst) 365
renal autoregulation, intravital microscopy (abst) 366
Nitric oxide synthase (NOS)
blockade, removal during HD (abst) 363
central/peripheral pressor effects (abst) 353
consequences of regulation (abst) 694
dexamethasone, IL-113, cAMP, MC (abst) 992
Ginseng Saponin effects (abst) 353
Heymann nephritis (abst) 692
IGF-1 aminoguanidine (abst) 685
inducible, regulation in MC 500
localization, mammalian kidneys (abst) 967
NO expression, IL-1j3, MC (abst) 990
RAS distribution, juxtaglomerular apparatus (abst). 670, 964
reabsorption of NLA, TGF responses 1252
Non-insulin dependent diabetes mellitus (NIDDDM)
DN type II 1781
hypertension, renal function, black subjects 1697
Nonimmunologic late renal graft loss, Nephrology
Forum 1470
Norepinephrine, RA pressure, renal urokinase (abst) 352
Nuclear pore complexes, MDCK cells (abst) 658
Nucleosomes bind to glomerular MC 1258
Nucleotides
extracellular, Ca, cortical TAL, Henle's loop (abst) 700
extracellular, renal handling (abst) 699
extracellular, renal tubular transport 1500
Nutritional assessment
amino acid-based dialysate, CAPD 1148
CAPD and HD compared (abst) 358, 359
rhGH, malnourished adults, CAPD (abst) 359
urea kinetic modeling, CAPD (abst) 358
urea kinetic modeling, one-compartment, HD (abst). . . . 970
0
Obstruction
proximal tubular cytoresistance 628
unilateral, nephropathy, Ang II 1285
Ochratoxin A, kidney and renal cell lines (abst) 965
OKT3
biphasic gratiulocytopenia, after one dose (abst) 1218
resistant rejection, FK506 (abst) 975
Oligonucleotides
genes, organ development (abst) 693
phosphorothioate, renal transport 1462
Oncogenesis, targeted, renal cell lines 388
One-compartment (blood) UKM, HD (abst) 970
One-line dialysate HD method (abst) 970
1-desamino-8-D-arginine vasopressin (DDAVP), EFI
(abst) 706
1,25-dihydroxycholecalciferol, ICAM-1, EC (abst) 968
1,25(OH)2D3 receptor level, uremia (abst) 665
Ontogeny
Ang2 receptor mRNA 1095
angiotensin receptors 140
epithelial polarity, ureteric bud cell culture (abst) 978
Opiate intoxication, extracorporeal detoxification (abst). . 1007
Organic cations, renal transport 1647
Organic ion excretion in kidney (abst) 681
Organic osmolytes
along rodent nephrons (abst) 679
chronic diuresis, urine concentration (abst) 664
effiux, CD cells, G-proteins (abst) 996
ischemia, free amino acids, cortex/outer medulla (abst) . 991
in mesangial cells 473
salt adaptation (abst) 664
Ornithine metabolism, experimental GN (abst) 678
Osmolality, extracellular and taurine effiux (abst) 678
Osseus malformations, nephronophthisis (abst) 1008
Osteoblastic intracellular pH and Ca, acidosis 1790
Osteopathy
femoral head necrosis, post-transplant (abst) 984
low turnover, long-term HD (abst) 1000
Osteopontin expression, kidney 1585
Ouabain-like factor, intracellular Ca, CD cells (abst) .. . . 1006
Oxidant-induced PT cell injury, Ca (abst) 343
Oxidative phosphorylation diseases, aminoaciduria 1101
Oxygen dependent expression, EPO mRNA, kidneys
(abst) 694
Oxygen radicals as biocompatibility markers (abst) 995
Oxytocin, natriuresis, hypertonic NaCl (abst) 666
P
P-cresol role, phagocyte function 510
Pancreas/kidney transplant, UTI, DM, NaHCO3 loss,
theophyllin (abst) 1001
Pantoprazole pharmacokinetics, HD (abst) 984
Para-aminohippurate (PAH)
excretion, without urine examination (abst) 970
secretion, a-ketoglutarate (abst) 663
Paraquat intoxication, hemoperfusion (abst) 359
Parathyroid hormone (PTH)
autoregulation of secretion (abst) 363
bone disease, pre-dialysis/dialysis 1434
bone disease, uremia, diabetes 1746
lung and right ventricle, CRF 158
PKC, adenylate cyclase desensitization 38
PTH-related protein receptor, Ca, CRF 1182
receptor down-regulation, uremia 1797
Parathyroidectomy
anaphylaxis, heparin, thrombocytopenia (abst) 1003
PTH receptor down-regulation, uremia 1797
serum phosphate concentration, HD (abst) 1000
Pediatric donor kidneys, age-matching (abst) 996
Peptide tyrosine, post-prandial natriuresis (abst) 682
Peripheral blood
T-lymphocyte subsets, immunosuppression (abst) 361
T-lymphocyte subsets, renal cell carcinoma (abst) 345
Peripheral vein, measurement vascular access
recirculation (abst) 356
Peritoneal dialysis
AGE products in dialysis fluid 1768
albumin-based solutions (abst) 358
assessing individual capacity 1187
exit-site infections, local antibiotics (abst) 982
exit-site/sinus-tract infections, sulcus fluid flow rate
(abst) 994
peritoneal macrophages characterized (abst) 1481
prescription, "clearance peak" model (abst) 371
sieving coefficient, small solutes (abst) 358
tidal, prescription, PET (abst) 369
Peritoneal equilibration test (PET)
compared, peritoneal permeability analysis (abst) 1217
diabetes, peritonitis 1760
tidal peritoneal dialysis (abst) 369
Peritoneal lymphatic pathways, albumin, RBC transport
(abst) 684
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Peritoneal mesothelium
endocytosis/transcytosis, albumin gold 1274
SITS and DIDS, anionic transport (abst) 683
Peritonitis
effect on PET with diabetes 1760
nitrate levels, CAPD (abst) 1217
peritoneal fibrosis, CAPD (abst) 358
Permcath complications, changing pattern (abst) 977
PGF1, TxB2, cyclosporin, post-transplant (abst) 360
pH
acidosis, trade-offs in, Nephrology Forum 1205
CAPD patients 269
cell volume, acidic cellular compartments (abst) 681
cytosolic, K conductance, PT (abst) 965
intracellular, lipid peroxidation, PT cells (abst) 681
K response, acute respiratory alkalosis 217
metabolic acidosis, anion gap patterns, HD (abst) 354
metabolic acidosis, CRF (abst) 355
osteoblastic intracellular, Ca, acidosis 1790
papillary gradient, CD urine, vasa recta, diuresis
(abst) 681, 987
transport, inner medullary CD, Nephrology Forum 333
urinary parameters, chronic renal acidosis 624
Phagocyte function and p-cresol 510
Pharmacokinetics
anti-infective therapies, RI (abst) 982
bumetanide (abst) 354
lopentol, RI (abst) 988
pantoprazole, HD (abst) 984
rHuIGF-1, dialysis 869
Phoshoinositide metabolism, muscarinic agonists, PT
(abst) 665
Phosphate serum concentration, parathyroidectomy, HD
(abst) 1000
Phosphoenolpyruvate carboxykinase (PEPCK) (abst) 664
Phosphoinositidase C activation, glomeruli (abst) 687
Phospholipase C
dinucleotides, AP4A receptors, MC (abst) 1007
extracellular ATP, c-fos, P2u-receptors, MC (abst) 669
Phospholipase D, serotonin, MC (abst) 688




aminoaciduria, OXPHOS defects 1101
PKC, E1-E2 transition, Na/K-ATPase (abst) 696
protein kinase sites, Na/K-ATPase (abst) 675
Plasma exchange, amyloidosis, cytotoxic drugs (abst) . . . . 1485
Plasma membranes, inositol lipid signalling (abst) 686
Plasmalogen phospholipid hydrolysis, hypoxic PT 1087
Plasminogen activators
inhibitor-i expression, lupus nephritis 148
plasmin, MMP-2 cascade, ECM degradation 1039
remodel ECM, metalloproteinases 49:S-12
Platelet activating factor (PAF)
endotoxin, glomerular resistance (abst) 676
gentamicin, mesangial cells 1346
Platelet-derived growth factor (PDGF)
distribution, PKC-a/, VSMC (abst) 670
FGF, IL-ip, NOS, MC (abst) 695
modulated by Ang II 131
tyrosine kinases, angiogenesis (abst) 660
tyrosine phosphorylation, MC (abst) 687
Platelets
adhesion, lipoxin synthesis, GN 1295
anti-idiotypic antibody detection, anti-HLA-I (abst) . . . 1483
PMN functions, uremia, immunoglobulin light chains
(abst) 969
Podocytes
adhesive phenotype, FSGS (abst) 689
injury, development of GS (abst) 986
injury, FGF, membranous nephropathy (abst) 677
single nephron albuminuria 1078
single nephron albuminuria (abst) 1217
undergo mitosis, not cell division, FGF (abst) 689
Polyacrylonitrile (PAN) membrane, drug kinetics, HD
(abst) 982
Polyamide membrane HD, lipid profiles (abst) 1485
Polyamines, RBC/plasma, HD (abst) 972
Polyarteritis nodosa, Wegener's granulomatosis (abst) . . . 1000
Polyclonal anti-lymphocyte antibodies, rejection (abst)... 1222
Polycystic kidney disease (PKD)
chloride/protein intake, hypertension (abst) 973
EC growth, abnormal regulation 715
EC transport, abnormal 720
EGF receptor, CPK mouse kidney 490
genetic study 728, 729
HLA-DRB1, PKD-i gene analysis, adults (abst) 996
molecular basis 715—732
new mouse mutant model 552
Polyethylene coating, cellulose membrane (abst) 966
Polymorphonuclear leukocytes, [Ca2I carbohydrate
metabolism, verapamil 1741
Polysulphone dialyzers
compared, AMBIO dialyzer (abst) 966
heat disinfection 638
reuse and protein loss 573
Polytetrafluoroethylene (PTFE) grafts, AV fistulae,
seroma formation (abst) 1484
Polyunsaturated free fatty acids, antidiuresis, vasopressin
(abst) 687
Post-prandial natriuresis, peptide tyrosine, renal function
(abst) 682
Post-prostatectomy syndrome 262
Pre-eclampsia, ARF (abst) 1004
Prednisolone, NS, children, bone metabolism (abst) 347
Pregnancy
post-transplant (abst) 369
pre-eclampsia, ARF (abst) 1004
successful in CAPD patient (abst) 1004
Tamm-Horsfall protein, urinary excretion (abst) 1004
Prenatal diagnosis of Alport syndrome 327
Pressimmun therapy, acute rejection (abst) 981
Primary hyperoxaluria type I (abst) 1482
Primary hypertension, ADPKD renal prognosis (abst) . . . 1002
Primary vasculitis
renal, leukocyte infiltration, ICAM-1, VCAM-1 (abst) .. 363
systemic, MHC class II alleles 294
Proliferative glomerulonephritis
anti-MPO, ischemia/reperfusion injury 1121
apoptosis, mesangial cell (abst) 688
apoptosis in repair process 114
Propafenone intoxication, hemoperfusion (abst) 988
Prorenin
plasma, CsA increases in bone marrow (abst) 966
serum, microalbuminuria, IDDM (abst) 1224
Prostacyclin synthase, IL-i, MC (abst) 686
Prostaglandins
bone disease, f32-M, IL-1f3 587
endothelin effects 795
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fibrinolysis, ET-1, ARF (abst) 996
NaCI delivery, medullary interstitium (abst) 668
peritoneal mesothelial cell synthesis 282
production, ET, dopamine (abst) 973
proteinuria, glomerular permeability, GN (abst) 1007
renal baroreceptor mechanism, renin secretion (abst). . . 985
Protectin, urinary, complement SC5b-9, cytokines, MGN. 1403
Protein, dietary
intake, hypertension, PKD (abst) 973
renal effects, early CRF (abst) 353
urine concentration in health and CRF 7
Protein-A immunoadsorption, life-threatening SLE (abst) . 967
Protein kinase C
a/n, VSMC, PDGF (abst) 670
Ang II effect, PT (abst) 696
E1-E2 transition, Na/K-ATPase (abst) 696
extracellular ATP, Na transport (abst) 705
isoforms, high glucose, VSMC 1057
isoforms in renal tissue 766
PTH, adenylate cyclase desensitization 38
verocytotoxin receptor, endothelial cells (abst) 705
Protein kinases
cAMP-mediated glomerular function (abst) 688
Na/K-ATPase phosphorylation (abst) 675
TGF-131, proteinase activity, LLC-PK1 cells (abst) . . . . 1003
Protein losses with reused dialyzers 573
Proteinase 3, ANCA inhibition, Wegener's
granulomatosis 1528
Proteins
BBM as markers, PT injury (abst) 965
GP280/GP330 expression, endocytosis (abst) 659
granzyme, expression in rejection 70
receptor-associated 39/45 kD, Heymann nephritis 432
sorting, polarized epithelial surface (abst) 658
synthesis, glomerular proteolysis, GS (abst) 1009
Proteinuria
anti-proteinuric effect, ACEi (abst) 1223, 1224
CsA-associated arteriopathy, albuminuria (abst) 1008
FGF, podocytes, membranous nephropathy (abst) 677
glomerular apo deposits, analbuminemia (abst) 706
L-arginine, GN, hypertension (abst) 1007
nephropathy, sulphated glycosaminoglycans (abst) 1224
PGE1, glomerular permeability, GN (abst) 1007
protein-overload, interstitial renal fibrosis 1546
SDS-PAGE method, children, NS (abst) 346
uninephrectomized female analbuminemic rats 442
Proteoglycans
collecting tubule principal cells, SV4O (abst) 698
MC production, LDL (abst) 690
perlecan, modulates MC (abst) 690
synthesized, compared glycosaminoglycans (abst) 690
Proteolysis, angiogenesis, cytokines (abst) 659
Proto-oncogenes
cell proliferation 718
diabetic renal hypertrophy 782
Proximal tubules
acute up-regulation, Na/P-cotransport 675
Ang II effect, PKC (abst) 696
Ca, oxidant-induced cell injury (abst) 343
calcium channel blockers, anoxic PT injury (abst) 702
catalytic activity, cathepsin S (abst) 1000
cell culture medium effect (abst) 680
cisplatin, Na-coupled uptake, BBM fluidity 1048
glucocorticoids, NaHCO3 cotransporter 1669
GP280/GP330 expression, endocytosis (abst) 659
gp330, endocytosis of aprotinin (abst)
HSP7O mRNA, ischemic injury (abst)
IL-8, INF-y, IL-1, TNF-a (abst)
injury, BBM protein markers (abst)
K conductance, cytosolic pH regulation (abst)
K transport, fluid reabsorption (abst)
lipid peroxidation, intracellular pH (abst)
lipid peroxidation, Na/K-ATPase (abst)
MCP-1, IL-la, TNF-a (abst)
mercury toxicity
monoclonal anti-APA antibodies, APA redistribution
(abst)
muscarinic agonists, phoshoinositide metabolism (abst).
Na, K reabsorption with K loading (abst)
Na/Pt uptake sensitivity (abst)
obstruction, cytoresistance, hypoxic injury
plasmalogen phospholipid hydrolysis, hypoxia
upregulation, IL-2rcE (abst)
Psoriasis, RAS, renal hemodynamics, CsA (abst)
Pulmonary hemorrhage, ANCA-positive vasculitis (abst)
Pulmonary hypertension/calcification, PTH, CRF
Purine nucleosides, ATP, mitogenic effect, MC (abst).
Purine nucleotide cycle, kidney cortex/medulla (abst)
Puromycin aminonucleoside (PAN)
US severity, MCP-1, TGF-/3 (abst)
mesangial cells, ROS
nephrosis, 43 dDal glycoprotein, GEC (abst)
Pyelonephritis
acute, RF, post-transplant (abst)
E. coli, uropathogenic virulence (abst)
Pyelons, acutely dilated, measurement by AP (abst)
Pyeloplasty, children with UUO (abst)
R
Racial differences
hypertension, allograft survival 1136
hypertension, NIDDM, renal function 1697
rBAT and heavy metal intoxication 1677
Reactive oxygen species, mesangial cells and PAN 811
Recombinant human erythropoietin (rHuEPO)
LH kinetics/biopotency, men, HD (abst) 1004
stimulates angiogenesis 740
Recombinant human growth hormone, malnourished
adults, CAPD (abst) 359
Recombinant human IGF-1
impaired metabolic response, dialysis patients 876
pharmacokinetics, dialysis patients 869
Recombinant IL-2, uremia, HBV vaccine non-responders
(abst) 1483
Red blood cells, polyarnines, HD (abst) 972
Reflux nephropathy, children, glomerular morphometry.. 1108
Refractory systemic vasculitis, thalidomide (abst) 672
Rejection. See also Immunosuppression
acute, Pressiummun therapy (abst) 981
acute allograft, granzyme expression 70
biopsy findings (abst) 703
chronic, IL-i, TGF-j3 (abst) 361
chronic transplant loss 1491
ICAM-1 and VCAM-1 1383
influence of age (abst) 997
local transcription, complement C3 (abst) 371
monoclonal anti-IL-2R antibody, prevention 708
monoclonal/polyclonal anti-lymphocyte antibodies
(abst) 1222
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OKT3 resistant, FK506 salvage (abst) 975
Renal acid-base transport, Nephrology Forum 333
Renal ammoniagenesis, ASA, salicylic/salicyluric acids
(abst) 664
Renal artery
endothelium-dependent dilation, oxidized Lp(a), HDL
(abst) 684
occlusion, hypertension, unilateral kidney (abst) 982
pressure, urokinase, norepinephrine (abst) 352
stenosis, fibromuscular dysplasia (abst) 1219
stenosis, renin mRNAlsecretion, BP (abst) 978
Renal baroreceptor mechanism, prostaglandins (abst) .. . . 985
Renal biopsy
adhesion molecule distribution (abst) 370
adult nephrotic syndrome (abst) 345
allograft rejection (abst) 703
Clq nephropathy (abst) 347
CsA-associated arteriopathy (abst) 998
glomerular disease (abst) 346
Wegener's granulomatosis (abst) 1222
Renal blood flow
flow dependence, pressure diuresis (abst) 685
hippurate clearance (abst) 1220
Renal cell carcinoma, peripheral T-celI subsets (abst) 345
Renal cell lines
adenovirus-mediated gene transfer 322
ochratoxin A distribution (abst) 965
targeted oncogenesis 388
Renal development
embryonic ureteric bud cell expression (abst) 661
GATA-3 expression 1597
induced nephron deficit (abst) 661
mitochondrial ATP-synthase (abst) 679
normal human, MMPs and TIMP, ARPKD (abst) 659
novel gene products identified (abst) 986
regulatory gene expression (abst) 661
sorbitol pathway, perinatal rats (abst) 678
transcription, Na/K-ATPase gene (abst) 680
transcription factor Kid-i (abst) 661
transcriptional modulation, kidney genes (abst) 669
transcriptional regulation (abst) 693
vasopressin mechanism of action (abst) 679
Wilm's tumor protein (abst) 661
Renal disease
ACEi, endothelin prevent RF/death 1319
ancient Babylonia 1811
progression, chemokine role 49:S-44
stretavidin, targeted therapy 1327
Renal failure. See also Acute renal failure; Chronic renal
failure
in MELAS (abst) 1219
pyelonephritis, post-transplant (abst) 362
Rf-1 gene identification (abst) 702
Renal function
Ang (1-7) response (abst) 975
cAMP as second messenger, organic anion transport
(abst) 977
endothelin effects 795
ET-1 and L-arginine (abst) 666
5HTia receptor agonist, BP (abst) 668
heavy metal exposure (abst) 971
hypertension, black NIDDM subjects 1697
ICV immunoneutralization of ANP (abst) 682
NO stimulation, ET-1, humans (abst) 707
peptide tyrosine, post-prandial natriuresis (abst) 682
post-lung transplant (abst) 704
post-sino-carotid denervation, ANP (abst) 668
sino-carotid denervation, ANP, endocrine function
(abst) 683
vasopressin, molecular level response (abst) 660
Renal functional reserve impairment, grafts (abst) 974
Renal glutaminase, protein deprivation (abst) 664
Renal glutamine metabolism 96
Renal growth hormone, IGF-1, ARF 1658
Renal hemodynamics
afferent arteriolar response, Tolrestat (abst) 1221
ANP, acute volemic stress (abst) 686
anti-thymocyte-antibody, complement (abst) 686
antiproteinuric effect, ACEi (abst) 1224
dopa i.v., normotensive ADPKD (abst) 1218
endothelin effects 795
indomethacin in neonates (abst) 342
L-arginine, proteinuria, GN, hypertension (abst) 1007
PGE1, proteinuria, GN (abst) 1007
RAS, psoriasis, CsA (abst) 704
RPP reduction, Ang II, renal nerve (abst) 1220
terminal respiratory failure (abst) 1220
urinary Na excretion, moxonidine (abst) 972
vascular endothelial growth factor (abst) 983
Renal infarction, terminal complement cascade 918
Renal injury. See Injury, renal
Renal insufficiency
aluminum toxicity (abst) 983
anti-infective therapy (abst) 982
chronic, K permeability disorders (abst) 974
guanidino compound metabolism 464
iodine monitoring, contrast medium (abst) 983
magnesium transport, cell membranes (abst) 983
pharmacokinetics, lopentol, RI (abst) 988
Renal osteodystrophy and acidosis, Nephrology Forum . . 1816
Renal papillary pH gradient, CD urine, vasa recta,
diuresis (abst) 681, 987
Renal perfusion pressure, Ang II, renal nerve (abst) 1220
Renal regeneration, clusterin expression, apoptosis 411
Renal replacement therapy (RRT)
Eastern Germany (1993) vs. GDR (1989) (abst) 1003
risk factors with DM (abst) 366
Renal reserve measurement, urinary flow rate (abst) 666
Renal transcription factor Kid-i (abst) 661
Renal vasculature
cortical/juxtamedullary, ET (abst) 684
renin-inhibition, natriuresis, EH (abst) 1217
vasomotor response propagation (abst) 676
Renal vein thrombosis, adult NS, fibrinolysis (abst) 1483
Renin-angiotensin-aldosterone system
nifedipine, EPO (abst) 683
nifedipine, nicardipine compared (abst) 683
Renin-angiotensin system (RAS)
cardiac interstitial fluid (abst) 703
NOS, juxtaglomerular distribution (abst) 670, 964
oncogene expression, Ca oscillations (abst) 669
renal hemodynamics, psoriasis, CsA (abst) 704
renal/systemic response, EH (abst) 703
suppressed, anemia, CRF (abst) 354
Renin gene expression
cellular regulation 1266
OM 2-kidney, 1-clip rats (abst) 685
renal baroreceptor mechanism, prostaglandins (abst) . . . 985
unilateral RAS, BP (abst) 978
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Renin secretion
juxtaglomerular cells, chloride (abst) 675
juxtaglomerular cells, ET (abst) 669, 985
juxtaglomerular cells, LDL, Lp(a) 45
magnesium, Na, relative heart weight (abst) 995
natriuresis inhibition, EH (abst) 1217
pressure-dependent, ADPKD (abst) 967
pressure-dependent, calcium (abst) 675
Reperfusion injury. See Injury, renal
Respiratory acidosis, osteoblastic intracellular pH, Ca . . . 1790
Respiratory failure, renal hemodynamics (abst) 1220
Rhabdomyolysis
case analysis (abst) 343
lipid-lowering agents, post-transplant (abst) 362
Rheumatoid arthritis, nephropathy (abst) 350
Richet, Professor Gabriel 49:S-2
Right ventricular hypertrophy, PTH, CRF 158
Russell's viper venom, nephrotoxicity 518
S
S-adenosylhomocysteine, erythrocytes, uremia
Salicylic/salicyluric acids, renal ammoniagenesis (abst) .
Salt
adaptation, organic osmolytes (abst) 664
adenosine, TAL, Henle's loop (abst) 681
cortico-papillary gradient, vasopressin V2r (abst) 668
delivery to medullary interstitium (abst) 668
loading, urinary neutral endopeptidase 855
Salt, dietary
adenosine-hypersensitivity, glomeruli (abst) 686
albuminuria, EH (abst) 992
ambulatory BP monitoring, EH (abst) 978
hyperfiltration, EH (abst) 366
restriction, calciuria, K-deprivation 899
sensitivity and vascular compliance 169
Salt transport
distal nephron segments, DNA synthesis (abst) 680
modulation, DNA synthesis 1615
Sandimmun-Neoral conversion (abst) 990
SC5b-9, urinary, CD59, cytokines, MGN 1403
Second messenger control, renin mRNA, juxtaglomerular
cells (abst) 669
Secondary hyperparathyroidism, bone disease, uremia,
DM 1746
Secondary membranoproliferative GN, Nephrology
Forum 643
Senior-Loken syndrome (abst) 662
Seroma formation, PTFE grafts as AV fistulae (abst).... 1484
Serotonin activates phospholipase D, MC (abst) 688
72 kD collagenase-IV gene, MC enhancer (abst) 974
Silibinin
cytoprotection, fibronectin turnover (abst) 673
cytoprotection, nephrotoxicity, SOD (abst) 971
Simian virus 40, proteoglycans, CD (abst) 698
Single nephron albuminuria 1078
Single nephron albuminuria (abst) 1217
Sino-carotid denervation
ANP, renal/endocrine function (abst) 683
ANP, renal function (abst) 668
Sinus-tract infections, sulcus fluid flow rate, PD (abst) . . . . 994
Smooth muscle a-actin (nSMA), IgAN, MC (abst) 364
Snake venom nephrotoxicity 518
Solute transport mechanisms, pulmonary epithelial 721
Somatostatin, cGMP synthesis, MC (abst) 666
Sonography
children with NS (abst) 346
EH, renal resistance index, age (abst) 986
medullaty nephrocalcinosis, adults (abst) 995
Sorbitol pathway, development (abst) 678
Staghorn calculi, ESWL monotherapy (abst) 345
Staphylococcus aureus
methicillin-resistant, GN 207
prophylaxis, CRIs (abst) 994
Steroids
NS, children, bone metabolism (abst) 347
NS, children, CsA, INF-y, IgE-Ril (abst) 346
NS, children, favorable course 1392
NS, children MP pulse therapy (abst) 348
Stilbene derivatives (SITS and DIDS), peritoneal
transport (abst) 683
Stretavidin, renal accumulation 1327
Sulcus fluid flow rate, PD exit-site infection (abst) 994
Sulmycin Implant, PD exit-site infection (abst) 982
Suiphated glycosaminoglycans, proteinuria, nephropathy
(abst) 1224
Superoxide dismutase (SOD)
cytoprotection, nephrotoxicity, silibinin (abst) 971
gene activation, nephron locus 536
SV4O T-oncogene, 92/72-Wa collagenase-IV, CD (abst) .. 665
Systemic lupus erythematosus (SLE)
antiphospholipid antibodies (abst) 369
circulating adhesion molecules (abst) 989
histology/clinical course (abst) 963
nucleosome binding, glomerular MC 1258
PAl-i, lupus nephritis 148
protein-A immunoadsorption (abst) 967
vascular access clotting (abst) 1484
T
T-cell hybridoma, HgC12-induced, cytokines (abst) 694
T-cell subsets
pre-transpiant immunosuppression (abst) 361
renal cell carcinoma (abst) 345
T-cells
Goodpasture's syndrome (abst) 690
receptors, IgA nephropathy 177
Tamm-Horsfall protein excretion, pregnancy (abst) 1004
Taurine
efflux, extracellular osmolality (abst) 678
reabsorption, furosemide (abst) 997
99mTcDMSA renal uptake rate, UUO, children (abst).... 344
Thalidomide, refractory systemic vasculitis (abst) 672
Theophyllin, HCO1 loss, UTI, DM, post-transplant
(abst) 1001
Thrombocytopenia, heparin, anaphylaxis, post-
parathyroidectomy (abst) 1003
Thrombosis
coagulation regulatory protein, CAPD (abst) 990
renal vein, adult NS, fibrinolysis (abst) 1483
vascular intra-access pressure 1364
Thrombotic microangiopathy, post-transplant (abst) 1482
Thromboxane B2 PGF1 cyclosporin, post-transplant
(abst) 360
Thromboxane (TxA2)
endotoxin, glomerular resistance (abst) 676
IL-I regulation, MC (abst) 686
long-term inhibition, lupus nephritis 1168
Tidal peritoneal dialysis prescription, PET (abst) 369
Tissue expression factor, interstitial renal fibrosis (abst) . . 1005
Tissue specific cell lines 388
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Toirestat, afferent arteriolar pressure (abst) 1221
Torasemide, dosages, CRF (abst) 992
Toxicity
heavy metal, rBAT, amino acids 1677
mercury, kidney cells 395
opiates, extracorporeal detoxification (abst) 1007
propafenone, hemoperfusion (abst) 988
Transcytosis, endocytosis of albumin gold 1274
Transdifferentiation, renal fibrogenesis (abst) 1002
Transferrin gene expression 1068
Transforming growth factor-n (TGF-/3)
an overview 49:S-19
ANP, growth suppression, MC (abst) 692
cell specific regulation, ECM (abst) 363
chronic allograft rejection (abst) 361
CsA, cell proliferation (abst) 1006
decorin mRNA, DN (abst) 678
GS, PAN, MCP-1 (abst) 691
LTBP, renal localization 733
mediates GS 49:S-59
mRNA detection, diabetes (abst) 351
neutral endopeptidase, EGF, VSMC (abst) 665
production, MC, glomeruli, high glucose (abst) 673
proteinase, LLC-PK1 cells, protein kinase (abst) 1003
wound healing (abst) 692
Transplantation. See also Allografts; Rejection
ABO-incompatible, autoimmune hemolytic anemia
(abst) 362
acute pyelonephritis, graft kidney, RF (abst) 362
adhesion molecules distribution, biopsy (abst) 370
ADPKD patients (abst) 368
allogeneic, long-term tolerance (abst) 706
aluminum toxicity (abst) 983
analgesic nephropathy, urothelial carcinoma (abst) 984
anti-HCV positive donors 236
anti-IL-2R MoAb prevents rejection (abst) 708
AP measurement, acutely dilated pyelon (abst) 964
AV regurgitation, hypertension, nephrosclerosis (abst) . . 981
C4d deposits, "early graft dysfunction" (abst) 971
cardiovascular events after (abst) 979
chronic loss 1491
coronary risk, elderly (abst) 368
CsA, plasma prorenin, bone marrow (abst) 966
de novo diabetic GS, post-transplant (abst) 970
enalapril, erythrocytosis (abst) 361
femoral head osteonecrosis, post-transplant (abst) 984
graft related HLA-antibodies (abst) 963
HCV and HBV after (abst) 1001
HLA-I antigen serum levels (abst) 359
HLA-identical, Na homeostasis, dopamine (abst) 708
hyperparathyroidism, allograft (abst) 965
hyperparathyroidism (abst) 370
hypertension, post-transplant (abst) 998
impairment RFR, recipients (abst) 974
lipid profiles, Lp(a) (abst) 357
lipoprotein, serum (abst) 1005
living donor (abst) 360
LVH in recipients (abst) 1004
lymphoma, EBV, post-transplant (abst) 980
lymphoma, post-transplant (abst) 988
malignancy, associated factors (abst) 980
malignant tumors after (abst) 1006
metabolic risk factors (abst) 979, 980
metabolism, FK506, post-transplant (abst) 977
microscopic polyarteritis, anti-MPO antibodies (abst) . . . 368
non-immunologic factors (abst) 1005
number of nephrons, pre-transpiant (abst) 707
pancreas/kidney, UT!, DM, NaHCO3 loss, theophyllin
(abst) 1001
predisposition, post-transplant DM (abst) 975
predisposition to erythrocytosis (abst) 975
pregnancy after (abst) 369
reactivated EBV, sero-diagnosis (abst) 1006
rhabdomyolysis, lipid-lowering agents (abst) 362
survival, diabetic/non-diabetic patients (abst) 981
thrombotic microangiopathy (abst) 1482
urinary proteins, 2-year graft function (abst) 994
urinary proteins, biochemistry characterized (abst) . . . . 1001
urinary TxB2, PGF1 cyclosporin (abst) 360
UT! bacterial spectrum (abst) 1005
vessel wall properties, BP (abst) 964
Triglycerides in nephrotic syndrome 566
Tuberculosis in HD unit (abst) 359
Tubular cells
distinctive adherence, E. coli (abst) 688
growth and exogenous glutamine 299
heme-induced cytoresistance 1336
1,25-D3 increases !CAM-1, EC (abst) 968
transport, extracellular nucleotides 1500
transport, renal organic cation 1647




Tubular regeneration, hypoxia, ET-i, autocrine growth
loop (abst) 693
Tubular salt load, DNA synthesis 1615
Tubulogenesis, impaired, of ADPKD cells 861
Tubuloglomerular feedback
glomerular pressure, analbuminemic rats (abst) 702
intratubular injections, NO blockade (abst) 695
NLA reabsorption 1252
Tubulointerstitial fibrosis, Ang II, UUO 1285
Tubulointerstitial injury, urine electrophoresis 988
Tumefactive megalocytic interstitial nephritis, E. coli
(abst) 986
Tumor necrosis factor-a (TNF-a)
biphasic increase, MRL-lpr mice 122
mRNA, commercial dialysate, NF-kB activity 1537
production, chronic HD 559
PTEC production, IL-8 (abst) 704
PTEC production, MCP-1 (abst) 705
Tumor necrosis factor (TNF)
endothelial cells, ligand receptors (abst) 677
endothelial cells, verocytotoxin receptor (abst) 705
12(R)-HETE, ion transport, colon (abst) 1005
21 -aminosteroids, ischemia/reperfusion injury (abst) 1222
2-methylcitric acid, uremia (abst) 964
Tyrosine kinases
EGF receptor, kidneys 774
endothelial cells, PDGF, angiogenesis (abst) 660
phosphorylation, COX I! regulation, IL-i/I 1354
phosphorylation, PDGF, mesangial cells (abst) 687
U
Ultra-fast computer tomography, coronary arteries (abst). . 967
Ultrafiltrate conductivity kinetic model (abst) 367
Ultrafiltration
charge selectivity 1242
dextran sulfate uptake, glomerular cells 945
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Ultraviolet irradiation, HD water disinfection (abst) 1481
Unilateral ureteral obstruction (UUO)
Ang II, tubulointerstitial fibrosis 1285
pycloplasty, children (abst) 344
Uninephrectomy
analbuminemia, hyperlipidemia, GS 442
plasma/urine ET-1 (abst) 1008
Urea kinetic modeling (Kt/V)
I32-M deposits, HD 1453
nutritional assessment, CAPD (abst) 358
one-compartment (blood), HD (abst) 970
predicting dialysis delivery 319
ultrafiltrate conductivity, PFD (abst) 367
Urea reduction ratio, dialysis delivery 319
Uremia
1,25(OH)2D3 receptor level (abst) 665
arterial/venous changes, independent of BP (abst) 963
f32-M deposits, math model 1453
calcitriol i.v., insulin sensitivity 200
carbamylated hemoglobin as index (abst) 1219
erythrocytes, S-adenosylhomocysteine 247
GFR elevation, glucagon, cAMP (abst) 685
granulocyte inhibitory protein (GIP) and DIP (abst).... 672
HBV vaccine non-responders, rIL-2 (abst) 1483
hepatocyte metabolism 1522
idiopathic nephrotic syndrome (abst) 348
immunoglobulin light chains, PMN functions (abst) .... 969
LDL metabolism, dialysis 1732
metabolites, serum concentrations (abst) 964
p-cresol, phagocyte function 510
PTH receptor down-regulation 1797
secondary hyperparathyroidism, bone disease, DM . . . . 1746
Ureteric bud cell expression
K channel (abst) 661
ontogeny, epithelial polarity (abst) 978
Urinalysis, heavy metal exposure (abst) 971
Urinary excretion
2-M, children, NS, proteinuria (abst) 346
f32-M, idiopathic membranous nephropathy (abst) 1218
enzymes, contrast media, nitrendipine (abst) 369
enzymes, infradian bioperiodicity, age (abst) 968
enzymes, renal tubular brush border (abst) 989
Urinary flow rate
dependence of pressure diuresis (abst) 685
renal reserve measurement (abst) 666
Urinary neutral endopeptidase, salt loading 855
Urinary parameters, pH in acidosis 624
Urinary proteins
biochemical characterization, post-transplant (abst). . . . 1001
concentration/intake, in health and CRF 7
excretion, contrast media, nitrendipine (abst) 369
excretion, pregnancy (abst) 1004
predict 2-year graft function (abst) 994
Urinary tract disease, ancient Babylonia 1811
Urinary tract infection (UTI)
bacterial spectrum, post-transplant (abst) 1005
post-pancreas/kidney transplant, DM, NaHCO3 loss,
theophyllin (abst) 1001
Urine
CD, papillary pH gradient, diuresis, vasa recta
(abst) 681, 987
concentration, organic osmolytes, diuresis (abst) 664
Urine electrophoresis, interstitial nephritis (abst) 988
Urodilatin
ET-1, renal microcirculation (abst) 1009
isolated perfused kidney/neonatal kidney cells (abst).
renal effects
Urokinase, RA pressure, norepinephrine (abst)
Urothelial carcinoma (abst)
UTP, extracellular, membrane voltage, MC (abst)
V
Vasa recta
diuresis, papillary pH gradient, CD urine (abst) . . . 681, 987
Vascular access
clotting, SLE, anticardiolipin antibodies (abst) 1484
clotting AV fistulae, coagulation abnormalities (abst) . . 1484
intra-access pressure, thrombosis 1364
peripheral vein/low blood flow methods (abst) 356
seroma formation, PTFE grafts as AV fistulae (abst) .. 1484
Vascular changes
arterial/venous, independent of BP, uremia (abst) 963
compliance, salt sensitivity 169
reactivity, CsA (abst) 360
renal resistance arteries, insulin (abst) 997
Vascular endothelial growth factor (VEGF)
human kidney receptors (abst) 660
renal hemodynamics (abst) 983
Vascular rejection, biopsy (abst) 703
Vascular smooth muscle cells (VSMC)
high glucose, PKC isoforms 1057
Na/H antiporter (NHE-1 isoform), SHR 78
PDGF, PKC-a/ (abst) 670
TGF-p, EGF, neutral endopeptidase (abst) 665
Vasculitis
ANCA-positive, pulmonary hemorrhage (abst) 365
leukocytes, ICAM-1, VCAM-1, IL-la (abst) 672
leukocytes, ICAM-1, VCAM-l (abst) 363
MHC class II alleles 294
pathogenesis, neutrophils (abst) 672
refractory systemic, thalidomide (abst) 672
Vasoactive substances
interact with urodilatin 1558
plasma factor, MCD, glomerular permeability (abst). . . 1218
U-937 monocyte MC adhesion (abst) 660
Vasoconstriction
endotoxin, preglomerular juxtamedullary vessels (abst). 1216
renal resistance arteries, insulin (abst) 997
Vasopressin
AQP-CD water channel (abst) 696
arginine, natriuresis (abst) 682
DDAVP, vasodilation, EH (abst) 706
hyaluronate hydrolases, urinary bladder (abst) 683
lithium reabsorption (abst) 683
polyunsaturated free FA, antidiuresis (abst) 687
renal development (abst) 679
renal response (abst) 660
WCH-CD endosome distribution, CD cells (abst) 675
Vasopressin V2 receptors
cortico-papillary NaC1 gradient (abst) 668
mutation, X-linked nephrogenic DI (abst) 344, 991
VCAM-1
allograft rejection, JCAM-1 1383
counter-receptors, crescentic GN (abst) 370
hemorrhagic fever with renal syndrome (abst) 350
leukocytes, renal vasculitis, ICAM-l (abst) 363
leukocytes, renal vasculitis, IL-la (abst) 672
Wegener's granulomatosis, SLE (abst) 989
Verapamil
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[Ca2], carbohydrate metabolism, PMNL 1741
DNA synthesis, adult MC proliferation (abst) 991
Verocytotoxin
producing E. col4 HUS (abst) 1222
receptor, endothelial cells (abst) 705
Vessel wall properties
ESRD, hyperhydration (abst) 964
post-transplant, hypertension (abst) 964
w
Water channels
AQP-CD water channel, vasopression (abst) 696
CHIP-FA amphibian (abst) 662
WCH-CD endosome distribution, CD cells (abst) 675
Wegener's granulomatosis
ANCA inhibits proteinase 3 1528
antiendothelial antibodies (abst)
circulating adhesion molecules (abst)
with microform of PAN (abst)
rabbit ATG therapy (abst)
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Wound healing, TGF-13 null mouse (abst)
x
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